{
  "2'-F-CTP": {
    "confidence": "medium",
    "en_full": "2'-Fluoro-cytidine triphosphate",
    "issue": "2'-F-CTP 是核苷酸化学修饰物的标准缩写，无通用中文译名。中文文献中通常保留英文原文或音译为'2'-氟胞苷三磷酸'，但业内更常用英文缩写。建议保留英文。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "http://field.10jqka.com.cn/20260227/c674963072.shtml",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "2'-F-UTP": {
    "confidence": "medium",
    "en_full": "2'-fluoro uridine 5'-triphosphate",
    "issue": "2'-F-UTP 是化学修饰核苷酸的标准缩写，无通用中文译名。搜索结果确认 2'-F（2'-fluoro）是 RNAi 药物研发中的常见修饰，UTP 为尿苷三磷酸。建议保留英文原文或按需补充为'2'-氟尿苷三磷酸'",
    "sources": [
      "https://pmc.ncbi.nlm.nih.gov/articles/PMC7969009/",
      "https://www.trilinkbiotech.com/blog/focus-on-2-fluoro-rna-aptamers-for-fighting-cancer/",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": "2'-F-UTP"
  },
  "2'-OMe-ATP": {
    "confidence": "medium",
    "en_full": "2'-O-methyl adenosine triphosphate",
    "issue": "2'-OMe-ATP 是核苷酸化学修饰的标准缩写，无通用中文译名。搜索结果中提及 2'-MOE（2'-O-methoxyethyl）等相关修饰，但 2'-OMe-ATP 作为具体化合物在中文文献中罕见。建议保留英文原文或按需音译为'2'-OMe-ATP（2'-O-甲基三磷酸腺苷）'，但业内通常直接使用英文缩写。",
    "sources": [
      "https://pmc.ncbi.nlm.nih.gov/articles/PMC8973385/",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag"
    ],
    "verified_at": "2026-04-22",
    "zh": "2'-OMe-ATP"
  },
  "2'-OMe-UTP": {
    "confidence": "high",
    "en_full": "2'-O-methyl uridine 5'-triphosphate",
    "issue": "",
    "sources": [
      "https://pmc.ncbi.nlm.nih.gov/articles/PMC8973385/",
      "http://field.10jqka.com.cn/20260227/c674963072.shtml",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag"
    ],
    "verified_at": "2026-04-22",
    "zh": "2'-OMe-UTP"
  },
  "2'-acetal levulinic ester (ALE) phosphoramidite": {
    "confidence": "high",
    "en_full": "2'-acetal levulinic ester (ALE) phosphoramidite",
    "issue": "",
    "sources": [
      "https://academic.oup.com/nass/article/52/1/35/1106686",
      "https://pubmed.ncbi.nlm.nih.gov/19485360/",
      "https://patents.google.com/patent/WO2010025566A1/en"
    ],
    "verified_at": "2026-04-22",
    "zh": "2'-缩醛乙酰丙酸酯（ALE）亚磷酰胺"
  },
  "32P-end-labeling": {
    "confidence": "high",
    "en_full": "32P-end-labeling",
    "issue": "",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": "32P末端标记"
  },
  "500 Å pore": {
    "confidence": "medium",
    "en_full": "500 Ångström pore",
    "issue": "搜索结果未直接出现'500 Å pore'的具体定义或标准译法。current_zh '500 Å孔径'的表述合理，Å为埃（Ångström）的符号，pore译为孔径。建议确认是否为特定纳米递送平台的技术参数，如为通用术语则保留现有译名。",
    "sources": [
      "https://pubmed.ncbi.nlm.nih.gov/39920702/",
      "https://www.ronatherapeutics.com/cn/news/45",
      "https://www.sohu.com/a/953037548_133140"
    ],
    "verified_at": "2026-04-22",
    "zh": "500 Å孔径"
  },
  "AGT": {
    "confidence": "high",
    "en_full": "Angiotensinogen",
    "issue": "current_zh 'AGT' 为缩写，应译为中文规范名称 '血管紧张素原'，英文全称为 'Angiotensinogen'",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/2741adb5cd13af9ce80b7526a5c5a1a1",
      "https://m.sgpjbg.com/hyshuju/3f2e5f640e03fa9c78acb599532b64a1.html",
      "https://bydrug.pharmcube.com/news/detail/85e7673fafed27f2514210fee4f59c32"
    ],
    "verified_at": "2026-04-22",
    "zh": "血管紧张素原"
  },
  "AJIPHASE®": {
    "confidence": "high",
    "en_full": "AJIPHASE®",
    "issue": "",
    "sources": [
      "https://ajibio-pharma.com/zh-TW/%E6%96%B0%E8%81%9E%E5%B4%97%E4%BD%8D/%E5%91%B3%E4%B9%8B%E7%B4%A0%E7%94%9F%E7%89%A9%E8%A3%BD%E8%97%A5%E6%9C%8D%E5%8B%99-ajiphase-%E6%8A%80%E8%A1%93%E7%94%9F%E7%94%A2%E7%9A%84%E9%A6%96%E5%80%8B%E5%95%86%E6%A5%AD%E8%97%A5%E7%89%A9%E7%8D%B2%E5%BE%97-FDA-%E6%89%B9%E5%87%86/",
      "https://www.ajinomoto.com/zh-CN/innovation/our_innovation/ajiphase",
      "https://cir.nii.ac.jp/crid/1390008613605437568"
    ],
    "verified_at": "2026-04-22",
    "zh": "阿吉相®"
  },
  "ANGPTL3": {
    "confidence": "high",
    "en_full": "Angiopoietin-like 3",
    "issue": "",
    "sources": [
      "https://www.modelorg.com/knowleges/1445387.html",
      "https://www.hangyan.co/charts/3566024114017666162",
      "https://www.mediecogroup.com/news/2075/"
    ],
    "verified_at": "2026-04-22",
    "zh": "血管生成素样蛋白3"
  },
  "AOF formulation": {
    "confidence": "low",
    "en_full": "Animal-Origin-Free formulation",
    "issue": "搜索结果未能直接确认 'AOF formulation' 的标准英文全称和中文译名。current_zh '无动物及人源成分（AOF）配方' 为推测性翻译，缺乏权威来源支持。建议人工复核原始文献或官方技术文档以确认准确定义。",
    "sources": [
      "https://news.yaozh.com/archive/46117.html",
      "https://www.frontiersin.org/articles/10.3389/fmolb.2026.1785592",
      "https://www.hangyan.co/reports/3841585074373919805"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "API sameness": {
    "confidence": "high",
    "en_full": "API Sameness",
    "issue": "",
    "sources": [
      "https://fda.gov/media/108970/download",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://www.cpa-italy.org/itrsi/pubblicazioni/studi-di-mercato/emerging-trends-in-the-biotech-apis-pipeline.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "API同一性"
  },
  "APOC3": {
    "confidence": "high",
    "en_full": "Apolipoprotein C-III",
    "issue": "",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/8d7dc27fad9de8dba30bb91256cb2596",
      "https://c.m.163.com/news/a/KIK7KE3B0514ADUL.html",
      "https://bydrug.pharmcube.com/news/detail/c3864109816813ce202b0d1c12ae954e"
    ],
    "verified_at": "2026-04-22",
    "zh": "载脂蛋白C-III"
  },
  "ASCVD": {
    "confidence": "high",
    "en_full": "Atherosclerotic Cardiovascular Disease",
    "issue": "",
    "sources": [
      "https://synapse.zhihuiya.com/blog/%E8%8C%B5%E8%AF%BA%E5%88%9B%E6%96%B0%E8%8D%AF%E7%89%A9%E7%AA%81%E7%A0%B4%EF%BC%8C%E5%85%A8%E7%90%83%E9%A6%96%E4%BE%8B%E9%80%86%E8%BD%ACascvd%E6%96%91%E5%9D%97%E6%96%B0%E8%8D%AF%E8%8E%B7fda%E5%8A%A0%E9%80%9F%E6%89%B9%E5%87%86%E8%B7%AF%E5%BE%84",
      "https://m.qiuyi.cn/ylnr/article_166.html",
      "https://www.zhihuiya.com/news/info_2502.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "动脉粥样硬化性心血管疾病"
  },
  "ASGPR": {
    "confidence": "high",
    "en_full": "Asialoglycoprotein Receptor",
    "issue": "",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/47602a70a88ad805eae372c04a85a526",
      "https://www.cn-healthcare.com/articlewm/20250514/content-1650096.html",
      "https://bydrug.pharmcube.com/news/detail/eeab7ee32b50d2910bc126957b81c596"
    ],
    "verified_at": "2026-04-22",
    "zh": "去唾液酸糖蛋白受体"
  },
  "ASMF": {
    "confidence": "medium",
    "en_full": "Active Substance Master File",
    "issue": "搜索结果未直接涉及ASMF术语定义。ASMF是药学术语，指Active Substance Master File（活性物质主文件），是药品注册中的技术文件类型，与RNAi药物研发管线的直接关联不明确。current_zh 'ASMF备案'表述不规范，应为'ASMF'或'活性物质主文件'。建议确认该术语在本领域的具体应用背景。",
    "sources": [
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://news.qq.com/rain/a/20260124A06K3C00",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Adaptive Laboratory Evolution": {
    "confidence": "medium",
    "en_full": "Adaptive Laboratory Evolution",
    "issue": "current_zh '适应性实验室进化' 与 'Adaptive Laboratory Evolution' 的标准中文译法略有差异。'Adaptive' 在生物学语境中通常译为'自适应'而非'适应性'，但两种表述在中文文献中均有使用。建议采用更规范的'自适应实验室进化'。搜索结果主要涉及寡核苷酸药物和基因组进化，未直接验证该术语的中文通用译名。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://m.ebiotrade.com/newsf/2026-2/20260209000451998.htm",
      "https://zhaogroup.chbe.illinois.edu/publications/HZ340.pdf"
    ],
    "verified_at": "2026-04-22",
    "zh": "自适应实验室进化"
  },
  "Ajinomoto Bio-Pharma Services": {
    "confidence": "high",
    "en_full": "Ajinomoto Bio-Pharma Services, Inc.",
    "issue": "",
    "sources": [
      "https://ajibio-pharma.com/",
      "https://www.ajibio-pharma.com/zh-TW/%E6%96%B0%E8%81%9E%E5%B4%97%E4%BD%8D/trio-pharmaceuticals-inc-%E5%92%8C-ajinomoto-bio-pharma-services-%E5%B0%B1%E6%96%B0%E5%9E%8B%E6%8A%97%E9%AB%94%E6%B2%BB%E7%99%82%E8%97%A5%E7%89%A9%E9%80%B2%E8%A1%8C%E9%96%8B%E7%99%BC%E5%90%88%E4%BD%9C/",
      "https://www.prnewswire.com/news-releases/ajinomoto-bio-pharma-services-hat-erfolgreich-eine-hochfunktionale-anzestrale-rna-ligase-entwickelt-301753008.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "味之素生物制药服务"
  },
  "Ajinomoto OmniChem": {
    "confidence": "medium",
    "en_full": "Ajinomoto OmniChem",
    "issue": "OmniChem 已于 2018 年与 Ajinomoto Althea 合并成立 Ajinomoto Bio-Pharma Services，但 OmniChem 作为业务部门名称仍在使用。中文译名基于 Ajinomoto（味之素）+ OmniChem 音译，但官方中文表述不统一，建议确认是否应更新为合并后的实体名称。",
    "sources": [
      "https://www.ajibio-pharma.com/zh-CN/news-post/ajinomoto-althea-and-omnichem-combine-to-form-ajinomoto-bio-pharma-services-reflecting-a-collective-range-of-services-offered-to-the-bio-pharma-industry/",
      "https://www.ajinomoto-omnichem.com/",
      "https://tracxn.com/d/companies/ajinomoto-omnichem/__7gOKTbpNp257J5h3L8jdOw_KYrGhRH8b-UD0XuslZao"
    ],
    "verified_at": "2026-04-22",
    "zh": "味之素欧姆尼凯姆"
  },
  "Amide linker": {
    "confidence": "high",
    "en_full": "Amide linker",
    "issue": "",
    "sources": [
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": "酰胺接头"
  },
  "Angiotensinogen": {
    "confidence": "high",
    "en_full": "Angiotensinogen",
    "issue": "",
    "sources": [
      "https://news.qq.com/rain/a/20241230A02NT800",
      "https://bydrug.pharmcube.com/news/detail/de56b6468d3b31dd203069e49c2fe362",
      "https://synapse.zhihuiya.com/drug/031fa8e24d244cd68b5117be53ba433a"
    ],
    "verified_at": "2026-04-22",
    "zh": "血管紧张素原"
  },
  "Antibody-Drug Conjugate": {
    "confidence": "high",
    "en_full": "Antibody-Drug Conjugate",
    "issue": "",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/463480ad78217c7bdaa6270bcef41c32",
      "https://synapse.zhihuiya.com/blog/%E5%85%A8%E7%90%83%E9%A6%96%E4%BE%8B%E5%8F%8C%E6%8A%97%E5%8F%8C%E6%AF%92%E7%B4%A0adc%E8%8D%AF%E7%89%A9%E6%8F%90%E4%BA%A4%E4%B8%B4%E5%BA%8A%E7%94%B3%E8%AF%B7",
      "https://bydrug.pharmcube.com/news/detail/a8d520a654e1850adac325019f2388ec"
    ],
    "verified_at": "2026-04-22",
    "zh": "抗体偶联药物"
  },
  "BD value": {
    "confidence": "high",
    "en_full": "Business Development transaction",
    "issue": "current_zh 'BD交易价值' 过于冗长；在医药行业语境中，'BD交易' 是标准简称，指企业间的商业合作、许可、收购等交易活动。搜索结果[4]标题明确出现 'BD交易活跃'，确认 'BD' 在此领域的通用含义。建议简化为 'BD交易'",
    "sources": [
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": "BD交易"
  },
  "BIOSECURE Act": {
    "confidence": "high",
    "en_full": "BIOSECURE Act",
    "issue": "",
    "sources": [
      "https://www.biocentury.com/topics/biosecure-act",
      "https://geneonline.news/%E7%BE%8E%E5%9C%8B%E6%8E%A8%E5%8B%95-biosecure-%E6%B3%95%E6%A1%88-2-0-%E5%BC%B7%E5%8C%96%E7%94%9F%E7%89%A9%E9%86%AB%E8%97%A5%E4%BE%9B%E6%87%89%E9%8F%88%E5%AE%89%E5%85%A8/",
      "https://ibinterviewquestions.com/guides/healthcare-investment-banking/biosecure-act-china-decoupling-reshoring"
    ],
    "verified_at": "2026-04-22",
    "zh": "《生物安全法案》"
  },
  "BTT activation": {
    "confidence": "low",
    "en_full": "Beta-Thalassemia Therapy",
    "issue": "搜索结果显示 'BTT' 在医学文献中指 'Beta-Thalassemia Therapy'（β-地中海贫血治疗），但在双靶点RNAi药物领域的具体含义不明确。current_zh 'BTT活化' 可能是特定技术术语或平台名，建议人工确认是否为专有技术缩写或误读。搜索结果主要涉及必贝特医药(BEBT)的双靶siRNA药物，与 'BTT activation' 的直接关联不清。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/564533635c9707ce1ae596974714f629",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://bydrug.pharmcube.com/news/detail/be97e6c870c76f26dfe3394a98047c9b"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Bachem": {
    "confidence": "medium",
    "en_full": "Bachem Holding AG",
    "issue": "Bachem 是瑞士知名的化学和生物技术公司，专门从事寡核苷酸、GalNAc 偶联物等 RNA 药物相关原料药和 CDMO 服务。搜索结果确认其在 RNAi 药物领域的重要地位，但未找到中文官方译名。作为国际知名企业，中文通常直接使用英文名 'Bachem'，无需强制汉化。",
    "sources": [
      "https://www.bachem.com/articles/oligonucleotides/galnac-delivering-promise-of-oligonucleotides/",
      "https://www.bachem.com/knowledge-center/galnac-delivering-promise-of-oligonucleotides/",
      "https://www.bachem.com/articles/oligonucleotides/silencing-the-gene-expression-asos-sirna-therapeutics/"
    ],
    "verified_at": "2026-04-22",
    "zh": "Bachem"
  },
  "BeBetter Med": {
    "confidence": "high",
    "en_full": "BeBetter Med, Inc.",
    "issue": "current_zh '必贝特' 为简称，应使用工商注册全名 '必贝特医药' 或 '广州必贝特医药股份有限公司'；根据搜索结果[2]，公司工商注册名为 '广州必贝特医药股份有限公司'，上市公司代码 SHA: 688759",
    "sources": [
      "https://flcube.com/?p=56254",
      "https://synapse.zhihuiya.com/organization/e8cb014d0dbbc49f59602b29e212c16c",
      "https://synapse.patsnap.com/organization/e8cb014d0dbbc49f59602b29e212c16c"
    ],
    "verified_at": "2026-04-22",
    "zh": "必贝特医药"
  },
  "Beyotime": {
    "confidence": "medium",
    "en_full": "Beyotime Pharmaceuticals",
    "issue": "current_zh '碧云天' 为错误译名。搜索结果明确显示该公司为'必贝特医药'，其双靶点siRNA药物BEBT-701已获NMPA批准进入临床试验。'碧云天'可能是对Beyotime的误译或混淆。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/be97e6c870c76f26dfe3394a98047c9b",
      "https://bydrug.pharmcube.com/news/detail/564533635c9707ce1ae596974714f629",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": "必贝特医药"
  },
  "Biologics License Application": {
    "confidence": "high",
    "en_full": "Biologics License Application",
    "issue": "",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a",
      "https://www.delveinsight.com/report-store/rna-interference-therapy-competitive-landscape"
    ],
    "verified_at": "2026-04-22",
    "zh": "生物制品上市许可申请"
  },
  "Biomaide": {
    "confidence": "low",
    "en_full": "Biomaide",
    "issue": "搜索结果中未找到 'Biomaide' 的明确定义或官方信息。搜索结果主要涉及 Bima（减重药物）、Arrowhead（RNAi 公司）等其他企业，与 Biomaide 无直接关联。current_zh '博迈德' 无法从搜索结果中验证。建议补充搜索或人工确认该术语的准确性和所属机构。",
    "sources": [
      "https://bydrug.pharmcube.com/report/detail/ae3f487b76ec4f539c8bcaace3daf55c",
      "https://bydrug.pharmcube.com/report/detail/c38fc881773444bebb80f59a21c45818",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "BirA/AviTag": {
    "confidence": "high",
    "en_full": "BirA/AviTag (Biotin Ligase/Avidin Tag)",
    "issue": "BirA/AviTag 是分子生物学工具术语，非药物或公司名。BirA 是大肠杆菌生物素连接酶，AviTag™ 是 Avidity 公司的专利技术标签。在学术和技术文献中通常保留英文原文，无通用中文译名。建议保留英文。",
    "sources": [
      "https://finance.sina.com.cn/stock/t/2026-04-22/doc-inhvinuk5738144.shtml",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://knowledge.nuclera.com/docs/quantification"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Bis-RNAi": {
    "confidence": "medium",
    "en_full": "Bis-RNAi (Dual-target RNAi)",
    "issue": "Bis-RNAi 是技术术语而非专有名词。搜索结果中未找到 'Bis-RNAi' 的明确定义，但大量文献使用'双靶点siRNA'、'双靶siRNA'、'双靶点小核酸药物'等表述。current_zh 保留英文原文是合理的，但在中文学术文献中通常译为'双靶点RNAi'或'双靶siRNA'。建议沿用 current_zh 或改为'双靶点RNAi'以符合中文表达习惯。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://bydrug.pharmcube.com/news/detail/564533635c9707ce1ae596974714f629",
      "https://www.siranbio.com/news/html/?31.html="
    ],
    "verified_at": "2026-04-22",
    "zh": "双靶点RNAi"
  },
  "C5": {
    "confidence": "high",
    "en_full": "Complement Component C5",
    "issue": "",
    "sources": [
      "https://www.cyagen.cn/articles/AE001104",
      "https://www.qudaojing.com/dwmxx/12895.html",
      "https://synapse.zhihuiya.com/target/6231d8d05d42336785bf5e69af5d0080"
    ],
    "verified_at": "2026-04-22",
    "zh": "补体C5"
  },
  "CDE": {
    "confidence": "high",
    "en_full": "Center for Drug Evaluation (CDE)",
    "issue": "",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/a7cfc3fc0d727b9252a9931fe86d8406",
      "https://bydrug.pharmcube.com/news/detail/aaceb0faa5d8ac4814bc2ea1363f88a3",
      "https://bydrug.pharmcube.com/news/detail/487031534c5bf82bb5db7ed5e0686610"
    ],
    "verified_at": "2026-04-22",
    "zh": "药品审评中心"
  },
  "CDMO": {
    "confidence": "high",
    "en_full": "Contract Development and Manufacturing Organization",
    "issue": "",
    "sources": [
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://m.cphi.cn/news/show-362639.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "合同开发与生产组织"
  },
  "CID fragmentation": {
    "confidence": "medium",
    "en_full": "Collision-Induced Dissociation fragmentation",
    "issue": "current_zh 中 'CID' 后的括号表述冗余。标准术语应为 'CID 碎裂' 或 '碰撞诱导解离碎裂'，无需在中文译名中重复缩写。搜索结果未直接涉及 CID fragmentation 的中文术语定义，confidence 基于该术语在质谱学中的通用性。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://www.phirda.com/artilce_26418.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "碰撞诱导解离碎裂"
  },
  "CLEA-LentiKats lipase formulation": {
    "confidence": "medium",
    "en_full": "Cross-Linked Enzyme Aggregates (CLEA) encapsulated in LentiKats lipase formulation",
    "issue": "术语属于生物催化领域专业技术，非RNAi药物研发相关；current_zh译名基本准确，CLEA为Cross-Linked Enzyme Aggregates缩写，LentiKats为商业化微胶囊载体品牌名",
    "sources": [
      "https://www.sciencedirect.com/science/article/abs/pii/S0168165620300304",
      "https://link.springer.com/protocol/10.1007/978-1-0716-2269-8_21?error=cookies_not_supported&code=ace72850-4b56-44da-8bf7-7f973c02aa6c",
      "https://www.sciencedirect.com/science/article/pii/S0141813022013538"
    ],
    "verified_at": "2026-04-22",
    "zh": "CLEA-LentiKats脂肪酶制剂"
  },
  "CMC development timeline": {
    "confidence": "high",
    "en_full": "Chemistry, Manufacturing, and Controls development timeline",
    "issue": "",
    "sources": [
      "https://cn.gii.tw/report/ires1933898-rnai-therapeutics-market-by-delivery-technology.html",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a",
      "https://chinamedglobal.com/blog/sirna-nucleic-acid-drug-registration-strategy"
    ],
    "verified_at": "2026-04-22",
    "zh": "CMC开发周期"
  },
  "CPG support": {
    "confidence": "low",
    "en_full": "CPG support",
    "issue": "搜索结果未能明确定义 'CPG support' 的具体含义。在双靶点 RNAi 药物领域，'CPG' 可能指 CpG（胞苷-鸟苷二核苷酸）或其他缩写，但搜索结果主要返回 CPHI 制药在线平台的文章，未提供 'CPG support' 作为技术术语的定义。建议：(1) 确认 CPG 的完整英文名称；(2) 查阅原始文献或技术文档以获得准确定义；(3) 若为专有技术名词，可能无通用中文译名。current_zh 'CPG载体' 可能是推测性翻译，缺乏权威支持。",
    "sources": [
      "https://m.cphi.cn/news/show-362639.html",
      "https://m.cphi.cn/news/search-htm-txtSearch-%E5%8F%8C%E9%9D%B6%E7%82%B9siRNA%E8%8D%AF%E7%89%A9-hide_search-4.html",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "CTA": {
    "confidence": "high",
    "en_full": "Clinical Trial Application",
    "issue": "",
    "sources": [
      "https://www.biospace.com/press-releases/arrowhead-pharmaceuticals-files-cta-for-investigational-aro-dimer-pa-the-first-dual-functional-rnai-therapeutic-for-the-treatment-of-mixed-hyperlipidemia",
      "https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-files-cta-investigational-aro-dimer-pa",
      "https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-files-cta-for-investigational-aro-dimer-pa-the-first-dual-functional-rnai-therapeutic-for-the-treatment-of-mixed-hyperlipidemia/"
    ],
    "verified_at": "2026-04-22",
    "zh": "临床试验申请"
  },
  "Calantha™": {
    "confidence": "medium",
    "en_full": "Calantha™",
    "issue": "Calantha™ 是商品名/商标名，非学术术语。根据搜索结果，Calantha™ 是美国 GreenLight Biosciences 公司开发的 RNAi 生物农药产品的商品名，有效成分为 Ledprona（双链RNA）。作为商标产品名，国内尚无统一的中文规范译名。建议保留英文原文，或根据产品在中国的注册情况补充中文商品名。",
    "sources": [
      "https://www.scilit.com/publications/f943600abdaefe036842dddcb97458ec",
      "https://link.springer.com/chapter/10.1007/978-3-031-81549-2_27?error=cookies_not_supported&code=0595873c-0e4e-4f52-b416-839046f11247",
      "https://chinawto.mofcom.gov.cn/article/jsbl/zszc/202310/20231003447824.shtml"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Calf Intestinal Alkaline Phosphatase": {
    "confidence": "high",
    "en_full": "Calf Intestinal Alkaline Phosphatase",
    "issue": "current_zh '小牛肠碱性磷酸酶' 缺少'道'字，规范译名应为'小牛肠道碱性磷酸酶'，与搜索结果[3][4]中权威生物化学试剂商的标准译法一致",
    "sources": [
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://m.cphi.cn/news/show-287207.html",
      "https://www.medchemexpress.cn/biology-dictionary/calf-intestinal-alkaline-phosphatase-cip.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "小牛肠道碱性磷酸酶"
  },
  "Candida antarctica lipase B": {
    "confidence": "high",
    "en_full": "Candida antarctica Lipase B",
    "issue": "",
    "sources": [
      "https://www.gilin.com.cn/essence0909899.html",
      "https://cj.sina.cn/articles/view/5953466437/162dab04506709blle?froms=ggmp",
      "https://onlinelibrary.wiley.com/doi/10.1002/adsc.202001367"
    ],
    "verified_at": "2026-04-22",
    "zh": "南极假丝酵母脂肪酶B"
  },
  "Category I": {
    "confidence": "medium",
    "en_full": "Category I",
    "issue": "搜索结果未直接涉及'Category I'的定义或分类标准。在RNAi药物研发背景下，'Category I'可能指药物分类、临床试验阶段分类或监管分类，但无法从搜索结果中确认其具体含义和规范中文译法。建议补充搜索或人工确认该术语在本领域的具体指代。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://bydrug.pharmcube.com/news/detail/564533635c9707ce1ae596974714f629",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": "第I类"
  },
  "Category II": {
    "confidence": "low",
    "en_full": "Category II",
    "issue": "搜索结果未涉及 'Category II' 的定义或中文译法。在双靶点RNAi药物研发背景下，'Category II' 可能指药物分类（如中国NMPA的创新药分类）、临床试验阶段分类或其他监管分类，但搜索结果未提供明确支持。建议补充搜索或人工确认该术语在本领域的具体含义。current_zh '第II类' 可能正确，但无法从搜索结果验证。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://bydrug.pharmcube.com/news/detail/564533635c9707ce1ae596974714f629"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Category III": {
    "confidence": "low",
    "en_full": "Category III",
    "issue": "搜索结果未能明确界定 'Category III' 在RNAi药物研发中的具体含义。该术语可能指：(1)临床试验分类（如中国NMPA的III期临床），(2)药物分类体系，(3)其他监管或技术分类。建议根据具体上下文（如是否指III期临床试验）确认后再译。current_zh '第III类' 可能混淆了'III期'（临床阶段）与'III类'（药物分类）的概念。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://www.nature.com/articles/s41392-024-02112-8",
      "https://news.yaozh.com/archive/46117.html"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Category IV": {
    "confidence": "low",
    "en_full": "Category IV",
    "issue": "搜索结果未包含 'Category IV' 的明确定义或中文对应。在双靶点RNAi药物研发领域，'Category IV' 可能指药物分类、临床试验分类或监管分类，但无法从提供的搜索片段确认其具体含义和规范中文译名。建议补充搜索或提供更多上下文。current_zh '第IV类' 为直译，但缺乏权威依据支持。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "http://stock.10jqka.com.cn/20260411/c675919380.shtml",
      "https://bydrug.pharmcube.com/news/detail/564533635c9707ce1ae596974714f629"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "ChemGenes": {
    "confidence": "high",
    "en_full": "ChemGenes Corporation",
    "issue": "ChemGenes是美国生物技术公司名称，无通用中文译名。虽然中文代理商可能有内部译法，但官方未采用统一的中文注册名。建议保留英文原文。",
    "sources": [
      "https://rnaibased-therapeutics.com/sponsor/chemgenes-corporation/",
      "https://www.chemegen.com/",
      "https://www.chemgenes.com/resources.php?id=2-and-3-o-methyl-rna"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Chinese IND": {
    "confidence": "high",
    "en_full": "China Investigational New Drug",
    "issue": "",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://flcube.com/?p=51737",
      "https://flcube.com/?p=52931"
    ],
    "verified_at": "2026-04-22",
    "zh": "中国IND"
  },
  "Class 3": {
    "confidence": "low",
    "en_full": "Class 3",
    "issue": "搜索结果未能明确界定 'Class 3' 在双靶点RNAi药物研发中的具体含义。'Class 3' 可能指药物分类、临床试验阶段、监管分类或技术分类，但搜索片段中未见相关定义。current_zh '第3类' 为通用数字译法，但缺乏上下文验证其准确性。建议补充更多背景信息或查阅原始文献以确认其确切含义。",
    "sources": [
      "https://www.giiresearch.com/report/del1950871-rna-therapies-competitive-landscape.html",
      "https://pdf.dfcfw.com/pdf/H3_AP202603091820414096_1.pdf",
      "https://mp.weixin.qq.com/s/jaHfnYV511qmM5y8N5VFtw"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Complement Factor B": {
    "confidence": "high",
    "en_full": "Complement Factor B",
    "issue": "",
    "sources": [
      "https://zh-cn.sanegenebio.com/sanegenebio-receives-nmpa-approval-to-initiate-clinical-trial-of-sirna-candidate-sgb-3383-for-complement-mediated-kidney-diseases/",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://data.pharmacodia.com/drugs/details/1764575534349549731"
    ],
    "verified_at": "2026-04-22",
    "zh": "补体因子B"
  },
  "Complete Response Letter": {
    "confidence": "high",
    "en_full": "Complete Response Letter",
    "issue": "",
    "sources": [
      "https://www.novartis.com/news/media-releases/novartis-receives-complete-response-letter-from-us-fda-inclisiran",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://www.zhihuiya.com/news/info_12579.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "完全答复函"
  },
  "Controlled pore glass": {
    "confidence": "high",
    "en_full": "Controlled Pore Glass",
    "issue": "",
    "sources": [
      "https://rna.bocsci.com/products/cpgs-for-oligo-synthesis-3885.html?page=9",
      "https://www.nature.com/articles/s41467-025-59526-3?error=cookies_not_supported&code=f70f0a8a-6cf7-42da-92e9-4157b63f9c27",
      "http://manu45.magtech.com.cn/Jwk_kqyxyj/CN/abstract/abstract1124.shtml"
    ],
    "verified_at": "2026-04-22",
    "zh": "受控孔径玻璃"
  },
  "Cross-Linked Enzyme Aggregates": {
    "confidence": "medium",
    "en_full": "Cross-Linked Enzyme Aggregates",
    "issue": "搜索结果未直接涉及 'Cross-Linked Enzyme Aggregates' 术语，current_zh 为合理的字面翻译。该术语在双靶点 RNAi 药物领域的具体应用背景未在搜索结果中明确体现，建议确认其在该领域的实际使用频率和规范性。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag",
      "https://news.yaozh.com/archive/46117.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "交联酶聚集体"
  },
  "CuAAC": {
    "confidence": "high",
    "en_full": "Copper-Catalyzed Azide-Alkyne Cycloaddition",
    "issue": "",
    "sources": [
      "https://www.ebiotrade.com/newsf/2025-10/20251029100233975.htm",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://www.hitgen.com/en/about-publications-42.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "铜催化叠氮-炔烃环加成"
  },
  "D-galactosamine": {
    "confidence": "high",
    "en_full": "D-galactosamine",
    "issue": "",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/47602a70a88ad805eae372c04a85a526",
      "https://www.frontiersin.org/articles/10.3389/fphar.2022.1090237/full",
      "https://www.biomart.cn/70612/news/3064652.htm"
    ],
    "verified_at": "2026-04-22",
    "zh": "D-半乳糖胺"
  },
  "DBCO": {
    "confidence": "high",
    "en_full": "Dibenzocyclooctyne",
    "issue": "",
    "sources": [
      "http://www.xbakbio.com/Article-3801974.html",
      "https://www.weihuasw.com/index.php?id=53727",
      "https://pdf.dfcfw.com/pdf/H3_AP202509241749656085_1.pdf?1758724918000.pdf="
    ],
    "verified_at": "2026-04-22",
    "zh": "二苯并环辛炔"
  },
  "DMF": {
    "confidence": "high",
    "en_full": "Drug Master File",
    "issue": "current_zh 'DMF备案' 为不规范表述。DMF 在生物医药领域标准译法为'药物主文件'或'药品主文件'，不应加'备案'二字。但在本搜索结果中未找到关于 DMF 的明确定义，搜索结果主要涉及 siRNA 药物、双靶点技术等内容，与 DMF 术语本身无直接关联。建议保留英文原文以避免误导。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://pdf.dfcfw.com/pdf/H3_AP202509241749656085_1.pdf?1758724918000.pdf=",
      "https://www.vicsdf.com/doc/8fee458eee50b57f"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "DMT-on HPLC purification handle": {
    "confidence": "high",
    "en_full": "DMT-on HPLC purification",
    "issue": "current_zh 中'把手'为误译，DMT-on 是寡核苷酸合成中的保护基团策略，不是物理把手。正确译法应为'DMT-on HPLC纯化'或'DMT保护HPLC纯化'",
    "sources": [
      "https://lcms.cz/paper/26697",
      "https://hal.science/hal-05131643v1/file/32%20-%20r%C3%A9actif%20DHA%20OrgLett2025.pdf",
      "https://hal.science/hal-05131643v1/document"
    ],
    "verified_at": "2026-04-22",
    "zh": "DMT-on HPLC纯化"
  },
  "DNase I": {
    "confidence": "high",
    "en_full": "Deoxyribonuclease I",
    "issue": "",
    "sources": [
      "https://synapse.zhihuiya.com/target/b4f2ba39224b4756b34e024f70379fe0",
      "https://synapse.zhihuiya.com/drug/00bcc5b8f97440b2a5e1b46e1984246d",
      "https://www.scbt.com/p/dnase-i-sirna-m-shrna-and-lentiviral-particle-gene-silencers"
    ],
    "verified_at": "2026-04-22",
    "zh": "DNase I"
  },
  "Deep Eutectic Solvent": {
    "confidence": "high",
    "en_full": "Deep Eutectic Solvent",
    "issue": "",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://pubmed.ncbi.nlm.nih.gov/39920702/",
      "https://www.ajchem-a.com/article_225661.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "深共熔溶剂"
  },
  "Dibenzocyclooctyne": {
    "confidence": "high",
    "en_full": "Dibenzocyclooctyne",
    "issue": "",
    "sources": [
      "https://discovery.researcher.life/article/dibenzocyclooctyne-conjugation-enhances-antigen-cross-presentation-and-t-cell-killing-for-potent-cancer-vaccines/ac7c876917613b83b56a6d62ef7e8fef",
      "https://www.163.com/dy/article/KQ8II3O805349C3G.html?f=post2020_dy_recommends",
      "https://www.zhihuiya.com/news/info_12579.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "二苯并环辛炔"
  },
  "Dual-Target RNAi Drug": {
    "confidence": "high",
    "en_full": "Dual-Target RNAi Drug",
    "issue": "",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://www.sirnaomics.com/en/news-room/press-release/20220621sirnaomics-to-present-the-latest-developments-of-dual-targeted-rnai-therapeutics-based-on-its-proprietary-galahead-program-at-the-4th-annual-rna-therapeutic-from-concept-to-clinic-symposium/",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": "双靶点RNAi药物"
  },
  "ECO GMP Manufacturing Center": {
    "confidence": "medium",
    "en_full": "ECO GMP Manufacturing Center",
    "issue": "搜索结果未直接提及 'ECO GMP Manufacturing Center' 的具体定义或权威来源。current_zh 的字面翻译合理，但无法从搜索结果中验证其是否为官方/规范译名。建议补充搜索相关机构官网或监管文件以确认。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://www.hangyan.co/reports/3841585074373919805",
      "https://m.cphi.cn/news/show-362639.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "ECO GMP生产中心"
  },
  "ECO Synthesis platform": {
    "confidence": "high",
    "en_full": "ECO Synthesis Manufacturing Platform",
    "issue": "",
    "sources": [
      "https://www.pharmtech.com/view/scaling-rna-therapeutics-sustainably-using-the-eco-synthesis-manufacturing-platform",
      "https://www.codexis.com/transformational-technologies/eco-synthesis-manufacturing-platform/",
      "https://www.codexis.com/investors/news-events/press-releases/detail/358/codexis-unveils-eco-synthesis-platform-for-large-scale"
    ],
    "verified_at": "2026-04-22",
    "zh": "ECO Synthesis平台"
  },
  "ECO ligase": {
    "confidence": "medium",
    "en_full": "ECO ligase",
    "issue": "搜索结果主要涉及Codexis公司的RNA连接酶技术，但未直接确认'ECO ligase'的完整英文名称或其是否为特定酶的缩写。ECO可能指E. coli来源或特定的工程化连接酶变体。current_zh '连接酶' 的翻译准确，但建议后续确认ECO的具体含义以完善术语库。",
    "sources": [
      "https://www.codexis.com/blogs/accelerating-scalable-and-sustainable-sirna-manufacturing-with-ligation-based-synthesis/",
      "https://www.biodragon.cn/files/uploads/wenxian/2024/CH1187_AGO4%E9%9D%9ERNAi%E7%9B%B8%E5%85%B3%E7%9A%84%E6%96%B0%E7%94%9F%E7%89%A9%E5%AD%A6%E5%8A%9F%E8%83%BD%E7%A0%94%E7%A9%B6.pdf",
      "https://www.codexis.com/investors/news-events/press-releases/detail/410/codexis-unveils-pioneering-enzymatic-synthesis-data-to"
    ],
    "verified_at": "2026-04-22",
    "zh": "ECO连接酶"
  },
  "FDA/CDER": {
    "confidence": "high",
    "en_full": "FDA Center for Drug Evaluation and Research",
    "issue": "",
    "sources": [
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://news.qq.com/rain/a/20240113A010QQ00",
      "https://mp.weixin.qq.com/s/9tsGeiIhsundH36qgK0NSg"
    ],
    "verified_at": "2026-04-22",
    "zh": "FDA/CDER"
  },
  "Factor XI": {
    "confidence": "high",
    "en_full": "Coagulation Factor XI",
    "issue": "",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/c0b9f7fe0356d1e098c638608cf7fd3b",
      "https://sirnaomics.com/en/news-room/press-release/20230412sirnaomics-launches-phase-i-clinical-trial-for-galnac-factor-xi-program/",
      "https://biopharmaapac.com/news/31/2943/sirnaomics-launches-phase-i-clinical-trial-for-galnac-factor-xi-program.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "凝血因子XI"
  },
  "Fall Line Endurance Fund": {
    "confidence": "low",
    "en_full": "Fall Line Endurance Fund",
    "issue": "搜索结果中仅出现 'Fall Line Capital'（农业科技基金投资方），未找到 'Fall Line Endurance Fund' 的明确定义或中文译名。该术语可能为特定基金产品名称，建议人工确认其准确性和中文官方译名。",
    "sources": [
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://agfundernews.com/greenlight-biosciences-raises-18m-series-d-rnai-biopesticide",
      "http://agfundernews.com/greenlight-biosciences-raises-18m-series-d-rnai-biopesticide.html"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Full-Length Product": {
    "confidence": "medium",
    "en_full": "Full-Length Product",
    "issue": "搜索结果主要涉及双靶点siRNA药物（RN5681等）的临床进展，未直接出现'Full-Length Product'的定义或中文对应。'全长产物'为该术语的字面直译，在RNAi/siRNA领域通常指未经修饰或完整的RNA产物。建议确认该术语在具体研究背景中的准确含义。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://www.ronatherapeutics.com/cn/news/45",
      "https://m.cphi.cn/news/show-362639.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "全长产物"
  },
  "G5 GalNAc support": {
    "confidence": "medium",
    "en_full": "Generation 5 GalNAc ligand",
    "issue": "搜索结果未直接出现'G5 GalNAc support'的完整定义。'G5'通常指第五代GalNAc配体技术，'support'可能指支持系统或载体平台。current_zh 'G5 GalNAc载体'为合理推断，但建议确认是否为Alnylam或其他公司的专有术语名称",
    "sources": [
      "https://m.cphi.cn/news/show-176928.html",
      "https://pmc.ncbi.nlm.nih.gov/articles/PMC12800395/",
      "https://bydrug.pharmcube.com/news/detail/47602a70a88ad805eae372c04a85a526"
    ],
    "verified_at": "2026-04-22",
    "zh": "G5 GalNAc载体"
  },
  "G5 ribofuranose": {
    "confidence": "medium",
    "en_full": "G5 ribofuranose",
    "issue": "搜索结果均为'ribofuranose-based GalNAc-conjugated siRNA'的学术文献，未找到'G5 ribofuranose'作为独立术语的明确定义。G5可能指代特定的核糖呋喃糖衍生物或修饰形式，但搜索结果中未明确说明G5的具体含义。current_zh译名'G5核糖呋喃糖'逻辑合理，但缺乏权威来源直接确认。",
    "sources": [
      "https://pmc.ncbi.nlm.nih.gov/articles/PMC12800395/",
      "https://discovery.researcher.life/article/ribofuranose-based-galnac-conjugated-sirna-enhances-the-liver-targeted-delivery-and-elicits-robust-rnai-mediated-gene-silencing/4804eb0e72bb3602bfbb6c4513221bc7",
      "https://pmc.ncbi.nlm.nih.gov/articles/PMC12969788/"
    ],
    "verified_at": "2026-04-22",
    "zh": "G5核糖呋喃糖"
  },
  "GDOC": {
    "confidence": "high",
    "en_full": "GalNAc Dual Oligonucleotide Conjugate",
    "issue": "current_zh 'GDOC平台' 过于简略，应展开为完整技术名称。搜索结果明确显示 GDOC 是必贝特医药（BEBT）的专有技术平台，全称为 'GalNAc 双寡核苷酸偶联'，用于开发双靶点 RNAi 药物（如 BEBT-701）。",
    "sources": [
      "http://cmnews.com.tw/tag/GDOC",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://bydrug.pharmcube.com/news/summary/tag/AGT"
    ],
    "verified_at": "2026-04-22",
    "zh": "GalNAc双寡核苷酸偶联技术平台"
  },
  "GDOC platform": {
    "confidence": "high",
    "en_full": "GalNAc Dinucleotide Oligonucleotide Conjugate platform",
    "issue": "current_zh 'GDOC平台' 过于简化；搜索结果明确显示 GDOC 是 'GalNAc Dinucleotide Oligonucleotide Conjugate' 的缩写，中文应译为 'GalNAc双寡核苷酸偶联平台'，这是必贝特医药等公司开发双靶点siRNA药物的专有技术平台",
    "sources": [
      "https://gdoc.org.uk/",
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://bydrug.pharmcube.com/news?searchKey=%E5%A4%A7%E7%9D%BF%E7%94%9F%E7%89%A9"
    ],
    "verified_at": "2026-04-22",
    "zh": "GalNAc双寡核苷酸偶联平台"
  },
  "GEMINI™": {
    "confidence": "medium",
    "en_full": "GEMINI™ Platform",
    "issue": "搜索结果未直接提供GEMINI™的完整英文全称或官方定义。current_zh 'GEMINI™平台' 基于领域背景（双靶点RNAi药物）推断合理，但缺乏权威信源明确确认该术语的具体含义和英文全称。建议补充查证GEMINI™是否为特定公司（如Alnylam、大睿生物等）的专有技术平台名称。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://bydrug.pharmcube.com/news/detail/b8714a2bace930f3b989dee6c7377c2d",
      "https://www.medsci.cn/search?q=Gemini"
    ],
    "verified_at": "2026-04-22",
    "zh": "GEMINI™平台"
  },
  "GMP-grade QC enzyme panel": {
    "confidence": "medium",
    "en_full": "GMP-grade QC enzyme panel",
    "issue": "搜索结果主要涉及GMP级别酶制剂（如IIs型内切酶）和siRNA药物研发，但未直接出现'GMP-grade QC enzyme panel'的完整表述。current_zh翻译合理，'质控酶组合'准确反映了QC enzyme panel的含义（质量控制用的酶制剂组合），建议保留。",
    "sources": [
      "https://integraterna.creative-biogene.com/cdmo/gmp-sarna-cdmo-service.html",
      "https://www.yeasen.com/h5/solutiondetail/3164",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": "GMP级质控酶组合"
  },
  "GT-multi-siRNA": {
    "confidence": "low",
    "en_full": "GT-multi-siRNA",
    "issue": "搜索结果未找到 'GT-multi-siRNA' 的明确定义或使用。搜索结果涉及双靶点 siRNA 药物（如大睿生物的 RN5681、迈威生物的 2MW7141）和学术文献中的 'dual gene-targeted multi-siRNA'，但均未提及 'GT-multi-siRNA' 这一具体术语。建议确认该术语是否为特定公司/项目的内部代号或是否存在拼写变异。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://synapse.zhihuiya.com/blog/%E8%BF%88%E5%A8%81%E7%94%9F%E7%89%A910%E4%BA%BF%E7%BE%8Eyuan%E5%8F%8C%E9%9D%B6sirna%E8%8D%AF%E7%89%A9newco%E5%85%A8%E7%90%83%E6%88%98%E7%95%A5%E8%B5%B7%E8%88%AA",
      "https://pubmed.ncbi.nlm.nih.gov/41471333/"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "GalAhead": {
    "confidence": "high",
    "en_full": "GalAhead™",
    "issue": "GalAhead是Sirnaomics公司的专有双靶点RNAi疗法平台名称，为商标术语（带™标记）。搜索结果显示中文文献中保留英文原文'GalAhead™'或'GalAhead (TM)'，未发现统一的中文规范译名。建议保留英文原文，current_zh中的'GalAhead™'已正确。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/7a670bb2864886b2e8dbfc731cdc9088",
      "https://www.sirnaomics.com/en/news-room/press-release/20220621sirnaomics-to-present-the-latest-developments-of-dual-targeted-rnai-therapeutics-based-on-its-proprietary-galahead-program-at-the-4th-annual-rna-therapeutic-from-concept-to-clinic-symposium/",
      "https://m.cphi.cn/news/show-199398.html"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "GalNAc-PA": {
    "confidence": "medium",
    "en_full": "N-acetylgalactosamine-phosphoramidite",
    "issue": "current_zh 中'亚磷酰胺'为音译，应改为'N-乙酰半乳糖胺-亚磷酰胺'以符合化学术语规范。GalNAc是N-acetylgalactosamine的缩写，PA是phosphoramidite的缩写，两者合并为GalNAc-PA，是siRNA合成中的关键偶联试剂。搜索结果中多次出现GalNAc递送平台相关内容，但未直接定义GalNAc-PA本身，confidence为medium而非high。",
    "sources": [
      "https://zh.tri-apex.com/info/insight/681.html",
      "https://sirnaomics.com/cn/news-room/press-release/20220815sirnaomics%E7%A0%94%E5%8F%91%E7%94%A8%E4%BA%8E%E4%BC%98%E5%8C%96galnac%E9%80%92%E9%80%81%E5%B9%B3%E5%8F%B0%E7%9A%84%E8%82%BD%E5%AF%B9%E6%8E%A5%E8%BD%BD%E4%BD%93-pdov-%E8%87%B4%E5%8A%9B%E4%BA%8E%E5%88%9B%E6%96%B0sirna%E7%96%97%E6%B3%95-2/",
      "https://tides.wuxiapptec.com/cn/resources/sirna-galnac-%E6%A1%88%E4%BE%8B%E5%88%86%E4%BA%AB%EF%BC%9A10%E4%B8%AA%E6%9C%88%E5%86%85%E5%B0%86%E4%B8%80%E4%B8%AA-sirna-galnac-%E5%80%99%E9%80%89%E5%8C%96%E5%90%88%E7%89%A9%E6%8E%A8%E8%BF%9B%E8%87%B3/"
    ],
    "verified_at": "2026-04-22",
    "zh": "N-乙酰半乳糖胺-亚磷酰胺"
  },
  "GalNAc-siRNA": {
    "confidence": "high",
    "en_full": "N-acetylgalactosamine-conjugated small interfering RNA",
    "issue": "current_zh 保留了英文缩写形式，应规范译为中文术语名称。GalNAc 是 N-acetylgalactosamine 的缩写，在生物医药领域的规范中文译名为 'N-乙酰半乳糖胺'，因此完整术语应为 'N-乙酰半乳糖胺-siRNA' 或 'GalNAc-siRNA（N-乙酰半乳糖胺-siRNA）'",
    "sources": [
      "https://zh.tri-apex.com/info/insight/699.html",
      "https://sirnaomics.com/cn/news-room/press-release/20220815sirnaomics%E7%A0%94%E5%8F%91%E7%94%A8%E4%BA%8E%E4%BC%98%E5%8C%96galnac%E9%80%92%E9%80%81%E5%B9%B3%E5%8F%B0%E7%9A%84%E8%82%BD%E5%AF%B9%E6%8E%A5%E8%BD%BD%E4%BD%93-pdov-%E8%87%B4%E5%8A%9B%E4%BA%8E%E5%88%9B%E6%96%B0sirna%E7%96%97%E6%B3%95-2/",
      "https://bydrug.pharmcube.com/news/detail/7a670bb2864886b2e8dbfc731cdc9088"
    ],
    "verified_at": "2026-04-22",
    "zh": "N-乙酰半乳糖胺-siRNA"
  },
  "GalT": {
    "confidence": "medium",
    "en_full": "Galactosyltransferase",
    "issue": "搜索结果主要涉及 GALNT3（N-乙酰半乳糖胺基转移酶-3）和 β-1,4-GalT-V（β-1,4-半乳糖基转移酶-V），而非通用的 GalT。GalT 作为缩写在双靶点 RNAi 药物领域的具体应用背景不明确，建议确认是否指特定的 GalT 亚型（如 GalT-I、GalT-II 等）或 GalNAc 偶联技术中的相关酶。",
    "sources": [
      "https://finance.sina.com.cn/wm/2026-04-21/doc-inhvhezh5024554.shtml",
      "https://patentimages.storage.googleapis.com/e0/90/a0/cc94a49ae72ddb/CN118139642A.pdf",
      "https://xuebao.shsmu.edu.cn/article/2024/1674-8115/1674-8115-2024-44-11-1460.shtml"
    ],
    "verified_at": "2026-04-22",
    "zh": "半乳糖基转移酶"
  },
  "GnTI": {
    "confidence": "medium",
    "en_full": "GNTI-122",
    "issue": "GNTI-122 是 GentiBio 公司开发的调节性 T 细胞（Treg）疗法，用于 1 型糖尿病治疗。GnTI 作为缩写术语在生物医药领域无统一的中文规范译名，建议保留英文原文。搜索结果未发现 'GnTI' 作为独立术语的定义，仅见 'GNTI-122' 作为具体药物代号。",
    "sources": [
      "https://synapse.patsnap.com/drug/8854f26c60804c19a68b8922566bae33",
      "https://www.breakthrought1d.org/grants/united-states/massachusetts/gnti-122-for-the-treatment-of-recently-diagnosed-type-1-diabetes/",
      "https://www.gentibio.com/wp-content/uploads/2024/08/GentiBio_IDS-Paris-2023_final.pdf"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "GreenLight Biosciences": {
    "confidence": "high",
    "en_full": "GreenLight Biosciences, Inc.",
    "issue": "GreenLight Biosciences 是美国生物技术公司，主要从事 RNA 农业应用（RNA 杀虫剂等），非双靶点 RNAi 药物研发公司。搜索结果 [2] 中提及的'绿叶制药'是中国公司，与 GreenLight Biosciences 无关。建议确认该术语是否为检索错误或领域不匹配。",
    "sources": [
      "https://greenlightbiosciences.com/",
      "https://www.zhihuiya.com/news/info_12150.html",
      "https://www.agropages.com/companydirectory/Detail-18427.htm"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "H1 subunit": {
    "confidence": "medium",
    "en_full": "H1 subunit",
    "issue": "搜索结果主要涉及RNAi药物研发和H1 Connect平台文献检索，未直接确认'H1 subunit'的具体含义。在RNAi领域，H1通常指RNA聚合酶III启动子(H1 promoter)，'H1 subunit'可能指相关蛋白亚基，但缺乏权威定义。current_zh'H1亚基'为合理的字面翻译，暂予保留，建议补充查证具体生物学含义。",
    "sources": [
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://www.siranbio.com/news/html/?31.html=",
      "https://connect.h1.co/article/1127008"
    ],
    "verified_at": "2026-04-22",
    "zh": "H1亚基"
  },
  "H2 subunit": {
    "confidence": "medium",
    "en_full": "Ribonuclease H2 subunit",
    "issue": "搜索结果主要指向RNASEH2A（核糖核酸酶H2 A亚基），但'H2 subunit'作为通用术语可指RNaseH2的任一亚基（A/B/C）。current_zh正确，但建议在具体应用中明确是H2A/H2B/H2C亚基。",
    "sources": [
      "https://www.antibodies-online.com/antibody/7174899/anti-Ribonuclease+H2,+Subunit+A+RNASEH2A+AA+1-299+antibody/",
      "https://www.origene.com/catalog/proteins/over-expression-lysates/ly416666-ribonuclease-h2-subunit-a-rnaseh2a-nm-006397-human-over-expression-lysate",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": "H2亚基"
  },
  "Hongene": {
    "confidence": "high",
    "en_full": "Hongene Biotechnology Corp.",
    "issue": "current_zh '兆维' 不完整，应为 '兆维科技'（官网及工商注册全称）",
    "sources": [
      "https://www.hongene.com/cn/news/hongene-supports-clinical-advancement-of-sirna-dnv001-using-proprietary-chemoenzymatic-ligation-platform/",
      "https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/90c73ab13a19a861640e0417a1ef8c3f",
      "https://www.hongene.com/news/6th-rnai-based-therapeutics-summit"
    ],
    "verified_at": "2026-04-22",
    "zh": "兆维科技"
  },
  "Host-Cell Protein": {
    "confidence": "high",
    "en_full": "Host-Cell Proteins",
    "issue": "",
    "sources": [
      "https://juejin.cn/post/7509377620318191650",
      "https://cjournal.hep.com.cn/1003-3734/CN/1179775702674874744",
      "https://www.zhihuiya.com/news/info_6258.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "宿主细胞蛋白"
  },
  "Huntingtin": {
    "confidence": "high",
    "en_full": "Huntingtin",
    "issue": "",
    "sources": [
      "https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3341?af=R",
      "https://www.sohu.com/a/981486268_100169988",
      "https://wjpr.s3.ap-south-1.amazonaws.com/article_issue/a558ff97fa7805e609bd7cd58f190e78.pdf"
    ],
    "verified_at": "2026-04-22",
    "zh": "亨廷顿蛋白"
  },
  "Hydroxyprolinol scaffold": {
    "confidence": "medium",
    "en_full": "Hydroxyprolinol scaffold",
    "issue": "current_zh 中的 '(tHP)' 缩写来源不明，搜索结果未见此缩写的标准定义。建议删除括号内的缩写，保留 '羟脯氨醇骨架' 作为规范译名。搜索结果主要为化学试剂商品页面和学术论文标题，未找到权威中文术语标准化文献。",
    "sources": [
      "https://www.semanticscholar.org/paper/A-programmable-dual-targeting-siRNA-scaffold-potent-Belgrad-Tang/8d9b46f15845339abdea08e35f5910c265e574d7",
      "http://www.0qy.com/chanpinfenlei/55693.html",
      "http://www.0qy.com/chanpinfenlei/141554.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "羟脯氨醇骨架"
  },
  "ICH Q11 Q&A": {
    "confidence": "high",
    "en_full": "ICH Q11 Q&As: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities)",
    "issue": "",
    "sources": [
      "https://db2.ouryao.com/ich/content.php?id=44&lang=cn",
      "https://www.scribd.com/document/984561825/q11%E9%97%AE-%E7%AD%94-%E5%8E%9F%E6%96%99%E8%8D%AF%E5%BC%80%E5%8F%91%E5%92%8C%E7%94%9F%E4%BA%A7-%E5%8C%96%E5%AD%A6%E5%AE%9E%E4%BD%93%E5%92%8C%E7%94%9F%E7%89%A9%E6%8A%80%E6%9C%AF%E7%94%9F%E7%89%A9%E5%AE%9E%E4%BD%93%E8%8D%AF%E7%89%A9-%E4%B8%AD%E6%96%87%E7%BF%BB%E8%AF%91%E5%85%AC%E5%BC%80%E5%BE%81%E6%B1%82%E6%84%8F%E8%A7%81%E7%A8%BF",
      "https://db.ouryao.com/ich/content.php?id=45"
    ],
    "verified_at": "2026-04-22",
    "zh": "ICH Q11问答"
  },
  "ICH Q13": {
    "confidence": "high",
    "en_full": "ICH Q13 Guideline on Continuous Manufacturing of Drug Substances and Drug Products",
    "issue": "",
    "sources": [
      "http://field.10jqka.com.cn/20260227/c674963072.shtml",
      "https://www.cnpharm.com/upload/resources/file/2023/05/11/137867.pdf",
      "https://lab.jgvogel.cn/c/2022-12-21/1243952.shtml"
    ],
    "verified_at": "2026-04-22",
    "zh": "ICH Q13指南"
  },
  "ICH Q2(R1)": {
    "confidence": "high",
    "en_full": "ICH Q2(R1) - Validation of Analytical Procedures",
    "issue": "ICH Q2(R1)是国际协调会(ICH)发布的指导原则编号，属于监管文件标准代码，无需中文译名。可保留英文原文或按需标注为'ICH Q2(R1)《分析方法验证指导原则(修订版1)》'，但作为术语本身应保持英文代码形式。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "http://field.10jqka.com.cn/20260227/c674963072.shtml",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "ICH Q3D(R2)": {
    "confidence": "high",
    "en_full": "ICH Q3D(R2): Guideline for Elemental Impurities",
    "issue": "",
    "sources": [
      "http://m.cnpharm.com/c/2022-09-09/991604.shtml",
      "https://bydrug.pharmcube.com/news/detail/cabe80939c755020cade18dd14f73e98",
      "https://finance.sina.com.cn/stock/med/2023-10-20/doc-imzrtfer1116219.shtml"
    ],
    "verified_at": "2026-04-22",
    "zh": "ICH Q3D(R2)：元素杂质指导原则"
  },
  "ICP-MS": {
    "confidence": "high",
    "en_full": "Inductively Coupled Plasma Mass Spectrometry",
    "issue": "搜索结果主要涉及RNAi药物、ADC药物等生物医药话题，与ICP-MS作为分析仪器的学术定义无直接关联。ICP-MS是通用分析技术术语，在双靶点RNAi药物研发中可能用于药物质量控制或杂质分析，但搜索结果未体现此应用场景。current_zh保留英文缩写形式，建议补充中文全称以便学术规范。",
    "sources": [
      "http://medical.sciencenet.cn/sbhtmlnews/2022/7/367922.shtm?id=367922",
      "https://api3.cls.cn/share/article/2332098?os=web&sv=859&app=",
      "https://mp.weixin.qq.com/s/jaHfnYV511qmM5y8N5VFtw"
    ],
    "verified_at": "2026-04-22",
    "zh": "电感耦合等离子体质谱法"
  },
  "IND-to-dosing gap": {
    "confidence": "medium",
    "en_full": "IND-to-dosing gap",
    "issue": "搜索结果未直接出现'IND-to-dosing gap'的标准定义或中文对标术语。current_zh 为合理的功能性翻译，准确反映了该术语在RNAi药物研发中的含义（从获得临床试验批准到患者首次给药之间的时间间隔），但无权威来源明确确认此中文译法。建议保留current_zh，因其在业界理解中已足够清晰。",
    "sources": [
      "https://flcube.com/?p=52931",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://www.zhihuiya.com/news/info_12579.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "IND获批与首次给药时间差"
  },
  "IVT": {
    "confidence": "high",
    "en_full": "In Vitro Transcription",
    "issue": "",
    "sources": [
      "https://www.siranbio.com/news/html/?31.html=",
      "https://mp.weixin.qq.com/s/5L1N4w-0e7CV2SdyUZ5AAg",
      "https://www.thermofisher.cn/us/en/home/life-science/rnai/silencer-sirna-construction-kit.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "体外转录"
  },
  "Just Climate": {
    "confidence": "low",
    "en_full": "Just Climate",
    "issue": "搜索结果无有效信息。'Just Climate' 在提供的搜索片段中未出现，搜索结果主要返回RNAi疗法和Nature Climate Change期刊的无关内容。无法确认 'Just Climate' 是否为公司名、项目名、平台名或其他专有名词。建议补充搜索或提供更多上下文信息以确认其身份和中文译名。",
    "sources": [
      "https://news.yaozh.com/archive/46117.html",
      "https://bydrug.pharmcube.com/news/detail/b46e648d440a805ce6cbf5da12b59514",
      "https://www.nature.com/subjects/rnai/nclimate"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Kd": {
    "confidence": "high",
    "en_full": "Dissociation Constant",
    "issue": "current_zh 'Kd值' 为口语表达，规范译名应为 'Kd（解离常数）' 或单独 'Kd' 时对应英文全称 'Dissociation Constant'；在学术文献中通常直接用 Kd 表示，中文可译为'解离常数'或'离解常数'",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/554b06dea2de9a5527766d88a0395191",
      "https://news.yaozh.com/archive/46117.html",
      "https://bydrug.pharmcube.com/news/detail/1fc4f1b87a1126ef25d47a7202f1f76a"
    ],
    "verified_at": "2026-04-22",
    "zh": "解离常数"
  },
  "Kinovate Life Sciences": {
    "confidence": "high",
    "en_full": "Kinovate Life Sciences, Inc.",
    "issue": "Kinovate Life Sciences 是寡核苷酸合成固体支持物供应商，非RNAi药物研发公司。在双靶点RNAi药物研发领域中属于上游原料/工具供应商，不是在研管线公司。建议确认搜索范围是否应包含供应链企业。",
    "sources": [
      "https://www.kinovate.com/",
      "http://www.cfdna.com.cn/archives/38013.html",
      "https://tracxn.com/d/companies/kinovate-life-sciences/__opymLQ4BgDLxqyxk6P1aRxkayf8TUYxjARGicb8UrnU"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "L96 ligand": {
    "confidence": "medium",
    "en_full": "L96 ligand",
    "issue": "L96是GalNAc偶联物中的特定配体分子，搜索结果主要涉及GalNAc-L96复合物用于RNA靶向递送。current_zh 'L96配体'准确反映了其作为配体的性质，但L96本身作为独立术语的中文规范译名在搜索结果中未明确出现，建议保留英文术语或补充说明为'L96肝靶向配体'以增加清晰度。",
    "sources": [
      "https://chemwhat.news/galnac-l96-a-key-molecule-for-efficient-rna-targeted-delivery/",
      "https://www.fcad.com/galnac-l96-a-key-molecule-for-efficient-rna-targeted-delivery/",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag"
    ],
    "verified_at": "2026-04-22",
    "zh": "L96配体"
  },
  "LDL-C": {
    "confidence": "high",
    "en_full": "Low-Density Lipoprotein Cholesterol",
    "issue": "",
    "sources": [
      "https://www.163.com/dy/article/KPJP9NUA05349C3I.html?f=post2020_dy_recommends",
      "https://finance.sina.com.cn/tech/roll/2026-04-13/doc-inhuihze5715515.shtml",
      "https://bydrug.pharmcube.com/news/detail/3dadb0acd28ff436209107fad4d1d390"
    ],
    "verified_at": "2026-04-22",
    "zh": "低密度脂蛋白胆固醇"
  },
  "LGC Biosearch Technologies": {
    "confidence": "high",
    "en_full": "LGC Biosearch Technologies",
    "issue": "LGC Biosearch Technologies 是国际知名的核酸合成和修饰技术供应商，属于 LGC 集团旗下业务部门。在中文生物医药文献中通常保留英文原名，无统一的中文规范译名。current_zh 保留英文是正确做法。",
    "sources": [
      "https://www.biospace.com/olix-pharmaceuticals-signs-agreement-with-lgc-biosearch-technologies-to-accelerate-production-of-asymmetric-sirna-for-the-treatment-of-androgenic-alopecia",
      "https://blog.biosearchtech.com/nucleic-acid-therapeutics-toolbox-givosiran",
      "https://blog.biosearchtech.com/whats-the-latest-in-aso-and-sirna-technologies"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Leloir glycosyltransferases": {
    "confidence": "high",
    "en_full": "Leloir Glycosyltransferases",
    "issue": "",
    "sources": [
      "https://www.mdpi.com/1422-0067/20/21/5263",
      "https://pmc.ncbi.nlm.nih.gov/articles/PMC6861944/",
      "https://pubmed.ncbi.nlm.nih.gov/31652818/"
    ],
    "verified_at": "2026-04-22",
    "zh": "Leloir糖基转移酶"
  },
  "Locked Nucleic Acid": {
    "confidence": "high",
    "en_full": "Locked Nucleic Acid",
    "issue": "current_zh '锁核酸' 不够规范，业界通用译名为 '锁定核酸' 或 'LNA'，前者更准确地反映 'Locked' 的含义",
    "sources": [
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag",
      "https://news.yaozh.com/archive/46117.html",
      "https://mp.weixin.qq.com/s/jaHfnYV511qmM5y8N5VFtw"
    ],
    "verified_at": "2026-04-22",
    "zh": "锁定核酸"
  },
  "Lp(a)": {
    "confidence": "high",
    "en_full": "lipoprotein(a)",
    "issue": "",
    "sources": [
      "https://www.ronatherapeutics.com/cn/news/45",
      "https://bydrug.pharmcube.com/news/detail/5c2d51491c51f91c928223b445db5db3",
      "https://www.hangyan.co/charts/3719703754413443071"
    ],
    "verified_at": "2026-04-22",
    "zh": "脂蛋白(a)"
  },
  "ManII": {
    "confidence": "low",
    "en_full": "ManII",
    "issue": "搜索结果未能找到 'ManII' 的明确定义。搜索结果主要涉及双靶点 siRNA 药物的研发进展（大睿生物、阳光诺和等），但未出现 'ManII' 作为具体术语、药物代号、靶点或技术名称的相关信息。建议确认：(1) ManII 是否为特定药物代号、靶点名称或技术术语；(2) 是否存在拼写变体（如 Man II、MANII 等）；(3) 在双靶点 RNAi 药物领域的具体应用场景。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Maywavee": {
    "confidence": "high",
    "en_full": "Mabwell",
    "issue": "term 'Maywavee' 为拼写错误，正确英文名为 'Mabwell'，中文规范译名为 '迈威生物'。搜索结果中多条权威医药媒体（新药情报库、医药魔方）均确认 Mabwell → 迈威生物的对应关系。",
    "sources": [
      "https://synapse.zhihuiya.com/blog/%E8%BF%88%E5%A8%81%E7%94%9F%E7%89%A910%E4%BA%BF%E7%BE%8Eyuan%E5%8F%8C%E9%9D%B6sirna%E8%8D%AF%E7%89%A9newco%E5%85%A8%E7%90%83%E6%88%98%E7%95%A5%E8%B5%B7%E8%88%AA",
      "https://synapse.zhihuiya.com/blog/%E8%BF%88%E5%A8%81%E7%94%9F%E7%89%A910%E4%BA%BF%E7%BE%8Eyuan%E5%8F%8C%E9%9D%B6%E7%82%B9sirna%E6%96%B0%E8%8D%AF%E6%88%90%E5%8A%9F%E7%AD%BE%E7%BD%B2newco%E4%BA%A4%E6%98%93",
      "https://bydrug.pharmcube.com/news/detail/06fbf6f2e1174c99eb5f99dc8cceaef8"
    ],
    "verified_at": "2026-04-22",
    "zh": "迈威生物"
  },
  "MutS Homolog 3": {
    "confidence": "high",
    "en_full": "MutS Homolog 3",
    "issue": "",
    "sources": [
      "https://m.chemicalbook.com/NewsInfo_76541.htm",
      "https://www.chemicalbook.com/NewsInfo_76541.htm",
      "https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=4437"
    ],
    "verified_at": "2026-04-22",
    "zh": "MutS同源物3"
  },
  "N-acetylgalactosamine": {
    "confidence": "high",
    "en_full": "N-acetylgalactosamine",
    "issue": "",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/47602a70a88ad805eae372c04a85a526",
      "https://www.frontiersin.org/articles/10.3389/fphar.2022.1090237/full",
      "https://pmc.ncbi.nlm.nih.gov/articles/PMC9794871/"
    ],
    "verified_at": "2026-04-22",
    "zh": "N-乙酰半乳糖胺"
  },
  "NAG37": {
    "confidence": "medium",
    "en_full": "NAG37",
    "issue": "NAG37 是一种亚磷酰胺单体/核苷类化学试剂，由华纳生物等公司生产，主要用于寡核苷酸药物合成（特别是GalNAc-siRNA偶联物）。作为化学试剂代号，无通用中文译名，保留英文原文。",
    "sources": [
      "https://www.huanaok.com.cn/display.php?id=866",
      "https://www.huarenscience.com/products/galnac-nag37-phosphoramidite.html",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "NDA": {
    "confidence": "high",
    "en_full": "New Drug Application",
    "issue": "",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://view.inews.qq.com/a/20260111A01O8S00",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": "新药申请"
  },
  "NMPA": {
    "confidence": "high",
    "en_full": "National Medical Products Administration",
    "issue": "",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/50c7a7663678f33babe4ab068721f47e",
      "http://prnasia.com/story/516413-1.shtml",
      "https://www.cn-healthcare.com/articlewm/20230204/content-1506229.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "国家药品监督管理局"
  },
  "Nitto Denko Avecia": {
    "confidence": "high",
    "en_full": "Nitto Denko Avecia Inc.",
    "issue": "current_zh 'Nitto Denko Avecia' 为英文原文，应补充中文表述。根据搜索结果，该公司是日本Nitto集团旗下的寡核苷酸药物制造服务商，中文通常称为'日本Nitto Denko Avecia公司'或'Nitto Denko Avecia'（保留英文全称）。建议保留英文全称作为主要标识，中文可标注为'日本Nitto Denko Avecia公司'或'Nitto Denko Avecia'。",
    "sources": [
      "https://pharmasource.global/directory/nitto-avecia/",
      "https://www.medvalley.cn/yiyao/35417.html",
      "https://avecia.com/"
    ],
    "verified_at": "2026-04-22",
    "zh": "日本Nitto Denko Avecia公司"
  },
  "NittoPhase HL": {
    "confidence": "high",
    "en_full": "NittoPhase HL",
    "issue": "NittoPhase HL 是 Kinovate Life Sciences（隶属日本 Nitto 集团）的专有产品名称，为寡核苷酸合成用高负载量固体载体。该产品名称在国际学术文献和行业中以英文商标形式使用，无统一的中文规范译名。建议保留英文原文或根据具体应用场景采用功能性描述（如'高负载量固体载体'）。",
    "sources": [
      "https://kinovate.com/downloads/05_NittoPhaseHL_Technical_paper.pdf",
      "https://www.kinovate.com/nittophasehl.php",
      "https://kinovate.com/downloads.php"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Norroa": {
    "confidence": "high",
    "en_full": "Norroa",
    "issue": "Norroa是GreenLight Biosciences开发的RNAi杀螨剂产品名，用于防治蜜蜂瓦螨。虽然在中文媒体中出现过'Norroa'的直接使用，但作为商业产品名称，暂无官方中文规范译名。建议保留英文原名。",
    "sources": [
      "https://www.chr1688.com/news/show-1801.html",
      "https://www.frontiersin.org/articles/10.3389/finsc.2026.1751606",
      "https://www.ronatherapeutics.com/cn/news/45"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Notice No. 21 of 2026": {
    "confidence": "medium",
    "en_full": "Notice No. 21 of 2026",
    "issue": "搜索结果未直接显示该通告的完整信息。根据上下文推断，该通告可能是中国国家药品监督管理局(NMPA)发布的药物临床试验批准通知书或相关监管文件，但无法从搜索片段中确认其确切内容和官方编号。建议查阅NMPA官方网站或相关监管公告以确认。",
    "sources": [
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://unifuncs.com/s/UdnoDlFI",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": "2026年第21号通告"
  },
  "Nuclease P1": {
    "confidence": "medium",
    "en_full": "Nuclease P1",
    "issue": "搜索结果未直接提及Nuclease P1的中文译名或详细定义。current_zh '核酸酶P1' 为合理的字面翻译，符合生物医药领域命名规范（核酸酶类酶制剂通常译为'核酸酶'），但无权威信源明确确认。建议保留现有译名。",
    "sources": [
      "https://discovery.researcher.life/article/a-targeted-rnai-of-rnai-strategy-to-overcome-nuclease-mediated-rnai-suppression-and-enhance-rnai-efficacy-in-lepidoptera-pest-cydia-pomonella/d44717eebcae3223993e779e453f5cb3",
      "https://www.nature.com/articles/s41392-024-02035-4?error=cookies_not_supported&code=d2b7d653-e154-4d37-80bd-7daccc20548a",
      "https://bydrug.pharmcube.com/news/detail/9552aed0b179d7b9c0ef5f88e799506e"
    ],
    "verified_at": "2026-04-22",
    "zh": "核酸酶P1"
  },
  "Nucleoside Triphosphate": {
    "confidence": "high",
    "en_full": "Nucleoside Triphosphate",
    "issue": "",
    "sources": [
      "https://www.163.com/dy/article/KPJP9NUA05349C3I.html?f=post2020_dy_recommends",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag"
    ],
    "verified_at": "2026-04-22",
    "zh": "核苷三磷酸"
  },
  "OPR&D": {
    "confidence": "medium",
    "en_full": "Organic Process Research & Development",
    "issue": "搜索结果未能确认 OPR&D 在双靶点RNAi药物研发领域的具体含义。current_zh '《有机工艺研究与开发》' 可能是期刊名或通用术语，但在本领域上下文中无法验证其准确性。建议确认 OPR&D 在该文献/文档中的具体指代。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://www.phirda.com/artilce_35053.html",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "PCSK9": {
    "confidence": "high",
    "en_full": "Proprotein Convertase Subtilisin/Kexin Type 9",
    "issue": "current_zh 为缩写形式，应补充中文全称或规范译名。PCSK9 是血脂领域重要靶点，中文规范译名为'前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型'或简称'PCSK9'",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/dbb6eb7d47e5b921b910f1ec4d982cd9",
      "https://news.yaozh.com/archive/46117.html",
      "https://mp.ofweek.com/medical/a956714457517"
    ],
    "verified_at": "2026-04-22",
    "zh": "前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型"
  },
  "PDE": {
    "confidence": "high",
    "en_full": "Phosphodiesterase",
    "issue": "current_zh '允许日暴露量' 为完全错误的术语，PDE 在生物医药领域指磷酸二酯酶（Phosphodiesterase），是一类重要的药物靶点。搜索结果中 PDE3/4 双抑制剂明确指向该含义。",
    "sources": [
      "https://paper.sciencenet.cn/htmlpaper/2026/1/202611516257474145439.shtm",
      "http://paper.sciencenet.cn/htmlnews/2026/1/558691.shtm",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": "磷酸二酯酶"
  },
  "PMO synthesis": {
    "confidence": "high",
    "en_full": "Phosphorodiamidate Morpholino Oligomer",
    "issue": "current_zh 'PMO合成' 仅为缩写+工艺名，应补全为完整术语名称。搜索结果[4]明确给出权威中文译名'磷酸二酰胺吗啉寡聚体'，与'吗啉寡核苷酸'为同义表述。",
    "sources": [
      "https://www.nature.com/articles/s41392-024-02112-8",
      "https://www.nature.com/articles/s41392-024-02112-8?error=cookies_not_supported&code=1a9dd43d-4417-4b27-8aff-984befb562cb",
      "https://caifuhao.eastmoney.com/news/20231101160940334617310"
    ],
    "verified_at": "2026-04-22",
    "zh": "磷酸二酰胺吗啉寡聚体"
  },
  "PVA entrapment": {
    "confidence": "high",
    "en_full": "Polyvinyl Alcohol (PVA) entrapment",
    "issue": "",
    "sources": [
      "https://pmc.ncbi.nlm.nih.gov/articles/PMC11243518/",
      "https://pubmed.ncbi.nlm.nih.gov/39920702/",
      "https://nature.com/articles/s41598-017-12351-1"
    ],
    "verified_at": "2026-04-22",
    "zh": "PVA包埋"
  },
  "Phosphodiester linker": {
    "confidence": "high",
    "en_full": "Phosphodiester linker",
    "issue": "",
    "sources": [
      "https://link.springer.com/article/10.1007/s11426-013-4912-y?error=cookies_not_supported&code=ef56b558-f9ab-4e67-b05c-4553db541ba1",
      "https://www.nature.com/articles/s41392-024-02035-4?error=cookies_not_supported&code=c2404747-88fb-41fd-a089-e7c4c688a712",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": "磷酸二酯接头"
  },
  "Polynucleotide Kinase (T4)": {
    "confidence": "high",
    "en_full": "T4 Polynucleotide Kinase",
    "issue": "current_zh '多核苷酸激酶（T4）' 的表述顺序不规范；业界通用译名为 'T4多聚核苷酸激酶' 或 'T4 PNK'，应将 T4 置于前位",
    "sources": [
      "https://www.chemicalbook.com/NewsInfo_5706.htm",
      "https://www.yiqi.com/product/detail_12529160.html",
      "https://www.qyresearch.com.cn/reports/4069216/t4-polynucleotide-kinase"
    ],
    "verified_at": "2026-04-22",
    "zh": "T4多聚核苷酸激酶"
  },
  "Poresyn Solutions": {
    "confidence": "medium",
    "en_full": "Poresyn Solutions",
    "issue": "Poresyn Solutions 是寡核苷酸合成材料和CDMO服务供应商，非药物开发公司。搜索结果显示其为B2B供应商，主要提供CPG固体支持物、LNA修饰试剂等寡核苷酸合成原料和服务。在双靶点RNAi药物研发领域中属于上游供应链角色，而非在研管线企业。建议保留英文原名，无需中文译名。",
    "sources": [
      "https://poresynsolutions.com/2026-top-10-oligonucleotide-manufacturing-companies/",
      "https://poresynsolutions.com/blog/",
      "https://poresynsolutions.com/"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Prime Synthesis CPG": {
    "confidence": "low",
    "en_full": "Prime Synthesis CPG",
    "issue": "搜索结果无法确认 'Prime Synthesis CPG' 的确切含义。结果[1]涉及 PrimeGene（JAK/ROCK双靶点拮抗剂），结果[4]涉及 CpG-ODN 免疫佐剂合成，但均未直接对应 'Prime Synthesis CPG' 这一完整术语。该术语可能是：(1)特定公司/平台的专有名称，(2)CPG（controlled pore glass）相关的合成技术组合，(3)搜索结果不相关。建议人工确认该术语的准确定义和来源。",
    "sources": [
      "https://synapse.patsnap.com/drug/483e9dfcd6e74754a597f2c688388987",
      "https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-025-02463-y",
      "https://m.cphi.cn/news/show-287207.html"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "PrimeMax siRNA CPG": {
    "confidence": "high",
    "en_full": "PrimeMax siRNA CPG",
    "issue": "PrimeMax siRNA CPG 是 LGC Biosearch Technologies 的商业产品名称和技术平台，属于专有商标产品。CPG 为 Controlled-Pore Glass（控制孔径玻璃）的缩写。该术语在中文生物医药文献中通常保留英文原文，无统一的中文规范译名。建议保留英文。",
    "sources": [
      "https://info.biosearchtech.com/primemax-sirna-cpg",
      "http://www.biosearchtech.com/nucleic-acid-chemistry-reagents-and-instruments/primemax-cpg/primemax-cpg/p/PRIMEMAX-001",
      "http://www.kbioscience.co.uk/nucleic-acid-chemistry-reagents-and-instruments/unmodified-oligo-synthesis-reagents/rna-oligonucleotides/cpg/c/rna-cpg"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Process Analytical Technology": {
    "confidence": "high",
    "en_full": "Process Analytical Technology",
    "issue": "",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://www.siranbio.com/news/html/?31.html="
    ],
    "verified_at": "2026-04-22",
    "zh": "过程分析技术"
  },
  "Process Atlas": {
    "confidence": "low",
    "en_full": "Process Atlas",
    "issue": "搜索结果与 'Process Atlas' 术语无关，均为中文医药行业新闻。无法从搜索结果中确认 Process Atlas 的含义、定义或中文译名。建议补充搜索或提供更多上下文信息。current_zh '工艺图谱' 可能是合理的推测，但缺乏权威来源支持。",
    "sources": [
      "https://www.163.com/dy/article/KQV0MKQK0552IJOG.html?f=post2020_dy_recommends",
      "https://news.qq.com/rain/a/20260124A06K3C00",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Process Mass Intensity": {
    "confidence": "medium",
    "en_full": "Process Mass Intensity",
    "issue": "搜索结果未直接涉及 'Process Mass Intensity' 术语。current_zh '工艺质量强度' 为合理的字面翻译，但无权威来源确认。建议补充查证制药工程或绿色化学领域的规范术语库。",
    "sources": [
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://www.163.com/dy/article/KPJP9NUA05349C3I.html?f=post2020_dy_recommends",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": "工艺质量强度"
  },
  "Q3M": {
    "confidence": "low",
    "en_full": "Q3M",
    "issue": "搜索结果中未找到 Q3M 作为独立术语的明确定义。搜索结果涉及 siRNA 药物（PCSK9、Vutrisiran、IBI3016、Zilebesiran 等），但均未提及 Q3M。Q3M 可能是：(1) 特定公司/项目的内部代号；(2) 某个在研药物的临床试验阶段标记；(3) 搜索无有效结果。建议补充搜索或提供更多上下文信息以确认其确切含义。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/3d9b4f01679dc45942f715f8dd1ff908",
      "https://zh.tri-apex.com/info/insight/659.html",
      "https://a7700.com/5272.html"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Q6M": {
    "confidence": "low",
    "en_full": "",
    "issue": "搜索结果中未找到 Q6M 的明确定义。搜索结果涉及小核酸药物领域的多个项目（Vutrisiran、Zilebesiran、IBI3016 等），但均未提及 Q6M。Q6M 可能是：(1) 某公司/项目的内部代码，(2) 尚未公开的在研代号，(3) 搜索词有误。建议补充搜索或提供更多上下文信息以确认其身份。",
    "sources": [
      "https://news.qq.com/rain/a/20260201A01TCE00",
      "https://zh.tri-apex.com/info/insight/659.html",
      "http://mp.weixin.qq.com/s?__biz=MzkwOTM4MjQwNg%3D%3D&chksm=c13ad770f64d5e66a7edc513408f83278a0fd87ede1aaab40d0f91950cecca8a4acb962ca2e4&idx=1&mid=2247487769&scene=21&sn=8db898689e3e3b21c0e7a6ee862f5cb5"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "QC biocatalyst": {
    "confidence": "low",
    "en_full": "QC biocatalyst",
    "issue": "搜索结果与'QC biocatalyst'无关，均为双抗ADC、RNAi药物的行业新闻。'QC biocatalyst'可能为特定公司/平台的专有术语或技术名词，搜索无有效结果。current_zh '质控生物催化剂'为字面翻译，但无法从搜索结果中验证其准确性。建议人工核查该术语的具体含义和来源。",
    "sources": [
      "https://api3.cls.cn/share/article/2332098?os=web&sv=859&app=",
      "https://news.qq.com/rain/a/20260124A06K3C00",
      "https://news.qq.com/rain/a/20251111A0160700"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "RADS™": {
    "confidence": "high",
    "en_full": "RNA molecules with superior Activity, Durability, and Safety",
    "issue": "",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/a0cd0c9c96c60dec6072883bc46bd60c",
      "https://pdf.dfcfw.com/pdf/H3_AP202603091820414096_1.pdf",
      "https://peterson.ventureradar.com/organisation/Argo%20Biopharmaceuticals/8bd750ae-03c9-4adc-b47d-01ed6e87057f/"
    ],
    "verified_at": "2026-04-22",
    "zh": "RADS平台"
  },
  "RNA interference": {
    "confidence": "high",
    "en_full": "RNA interference",
    "issue": "",
    "sources": [
      "https://www.ronatherapeutics.com/cn/news/45",
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://www.delveinsight.com/report-store/rna-interference-therapy-competitive-landscape"
    ],
    "verified_at": "2026-04-22",
    "zh": "RNA干扰"
  },
  "RNA-Induced Silencing Complex": {
    "confidence": "high",
    "en_full": "RNA-Induced Silencing Complex",
    "issue": "",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://news.yaozh.com/archive/46117.html",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": "RNA诱导沉默复合体"
  },
  "RNase A": {
    "confidence": "high",
    "en_full": "Ribonuclease A",
    "issue": "",
    "sources": [
      "https://www.emedclub.com/information/view/17eb20ada6ff11ebb602b8599f3054c8",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://www.inovogen.com/product/944.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "核糖核酸酶A"
  },
  "RNase H": {
    "confidence": "high",
    "en_full": "RNase H (Ribonuclease H)",
    "issue": "",
    "sources": [
      "https://html.rhhz.net/YXXB/html/20200403.htm",
      "https://pdf.dfcfw.com/pdf/H3_AP202603091820414096_1.pdf",
      "https://en.dascapital.cn/%E8%A1%8C%E7%A0%94-rna%E6%97%B6%E4%BB%A3%E5%8A%A0%E9%80%9F%EF%BC%9Frna%E8%B5%9B%E9%81%93%E6%A2%B3%E7%90%86/"
    ],
    "verified_at": "2026-04-22",
    "zh": "核糖核酸酶H"
  },
  "RNase Inhibitor": {
    "confidence": "high",
    "en_full": "RNase Inhibitor",
    "issue": "current_zh 保留英文原文不够规范，应译为'RNase抑制剂'或'核糖核酸酶抑制剂'，这是生物医药领域的标准中文术语",
    "sources": [
      "https://www.emedclub.com/information/view/17eb20ada6ff11ebb602b8599f3054c8",
      "https://www.sigmaaldrich.cn/CN/en/search/rnase-inhibitors?focus=products&page=1&perpage=30&sort=relevance&term=rnase+inhibitors&type=product",
      "https://www.siranbio.com/news/html/?31.html="
    ],
    "verified_at": "2026-04-22",
    "zh": "RNase抑制剂"
  },
  "RNase T1": {
    "confidence": "medium",
    "en_full": "Ribonuclease T1",
    "issue": "搜索结果主要涉及RNAi药物研发进展，未直接验证RNase T1的中文译名。current_zh '核糖核酸酶T1' 为标准学术译法，符合生化术语规范，但搜索结果中无权威来源明确确认此译名。",
    "sources": [
      "https://www.creative-biogene.com/RNase-T1-EMNT2029-864-23.html",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://en.dascapital.cn/%E8%A1%8C%E7%A0%94-rna%E6%97%B6%E4%BB%A3%E5%8A%A0%E9%80%9F%EF%BC%9Frna%E8%B5%9B%E9%81%93%E6%A2%B3%E7%90%86/"
    ],
    "verified_at": "2026-04-22",
    "zh": "核糖核酸酶T1"
  },
  "RSC 2.0 modification": {
    "confidence": "low",
    "en_full": "RSC 2.0 modification",
    "issue": "搜索结果未能找到 'RSC 2.0 modification' 的明确定义或权威来源。搜索结果主要返回 RSC Publishing（英国皇家化学会出版社）的文章，但这些文章标题中并未出现 'RSC 2.0 modification' 术语。该术语可能是：(1) 特定公司或研究团队的专有技术术语，(2) 尚未广泛发表的新兴技术，(3) 搜索词可能需要调整。建议保留英文原文，待获得更多权威信息后再确定中文译名。",
    "sources": [
      "https://pubs.rsc.org/en/content/articlehtml/2024/cb/d4cb00247d",
      "https://pubs.rsc.org/en/content/articlehtml/2025/cb/d4cb00247d",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "RiboGalSTAR™": {
    "confidence": "high",
    "en_full": "RiboGalSTAR™",
    "issue": "RiboGalSTAR™ 是瑞博生物自主研发的专有肝靶向递送平台技术的商标名称，属于技术平台品牌，无对应的中文规范译名。建议保留英文原文，不进行中文翻译。",
    "sources": [
      "https://www.sohu.com/a/986386531_639898",
      "https://money.udn.com/money/story/123828/9392978",
      "https://www.ribolia.com/media-center/our-products-news/125"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Ribonuclease T1": {
    "confidence": "high",
    "en_full": "Ribonuclease T1",
    "issue": "",
    "sources": [
      "https://www.amyjet.com/featured/Ribonuclease-T1.shtml",
      "https://www.creative-biogene.com/RNase-T1-EMNT2029-864-23.html",
      "https://www.targetmol.cn/compound/ribonuclease_t1"
    ],
    "verified_at": "2026-04-22",
    "zh": "核糖核酸酶T1"
  },
  "Roche Custom Biotech": {
    "zh": "罗氏定制生物技术"
  },
  "SBIA": {
    "confidence": "medium",
    "en_full": "CDER Small Business & Industry Assistance",
    "issue": "搜索结果中SBIA主要指FDA的CDER Small Business & Industry Assistance项目，但在双靶点RNAi药物领域的具体含义需要澄清。current_zh为'SBIA'（未翻译），建议确认是否指FDA项目或其他领域特定缩写。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://zh-cn.sanegenebio.com/pipeline/",
      "https://www.zhihuiya.com/news/info_11558.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "CDER小企业/产业协助计划"
  },
  "SBS": {
    "confidence": "medium",
    "en_full": "SBS Genetech",
    "issue": "SBS 在生物医药领域有多个含义：(1) SBS Genetech - 中国生物试剂公司，主营 siRNA、miRNA 等 RNAi 试剂；(2) 可能为其他缩写。搜索结果主要指向 SBS Genetech 公司，但在双靶点 RNAi 药物研发领域的具体应用场景不明确。建议根据上下文确认是指公司名还是技术术语。",
    "sources": [
      "https://www.sbsgenetech.com/rna-silencing",
      "https://bydrug.pharmcube.com/news/detail/564533635c9707ce1ae596974714f629",
      "https://bydrug.pharmcube.com/news/detail/7f1d7ea77e2e1e0b59b61fda17316bf6"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "SMART Digest RNase T1 kit": {
    "confidence": "high",
    "en_full": "SMART Digest™ RNase T1 Kit",
    "issue": "",
    "sources": [
      "http://www.thermofisher.com/order/catalog/product/60120-101",
      "https://commerce.thermofisher.com/order/catalog/product/60120-101",
      "https://www.perfinity.com/oligonucleotide-characterization"
    ],
    "verified_at": "2026-04-22",
    "zh": "SMART Digest RNase T1试剂盒"
  },
  "SPOS": {
    "confidence": "medium",
    "en_full": "Solid Phase Organic Synthesis",
    "issue": "搜索结果主要涉及siRNA药物管线和小核酸领域进展，未直接验证SPOS术语的中文译名。current_zh '固相合成（SPOS）'在学术文献中为通用译法，但搜索结果未提供独立确认。建议补充查证SPOS在核酸合成领域的权威定义。",
    "sources": [
      "https://www.163.com/dy/article/KQF9AT4C05198UNI.html?clickfrom=w_tech",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://www.sohu.com/a/982375140_133140"
    ],
    "verified_at": "2026-04-22",
    "zh": "固相合成"
  },
  "ST Pharm": {
    "confidence": "high",
    "en_full": "Sirnaomics (ST Pharm)",
    "issue": "current_zh 'ST Pharm' 为英文缩写，应使用中文规范译名 '圣诺医药'。根据搜索结果，ST Pharm 是韩国 Dong-A Socio Group 旗下的 CDMO 公司，但在中国市场更知名的是其关联公司圣诺医药（Sirnaomics），两者在双靶点 RNAi 药物领域有业务关联。建议确认具体指代对象。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/ee876b55ad30e78d60c591591c6ddf74",
      "https://www.stpharm.co.kr/en/ir/ir-materials/download/439/%25E3%2580%258C%25EB%25B0%2598%25EC%25B6%259C%25E3%2580%258DST%2520PHARM_IR%2520material_Aug_2022.pdf%3Fdownload%3D1",
      "https://www.stpharm.co.kr/ko/ir/ir-materials/download/1364/%E3%80%8C%EB%B0%98%EC%B6%9C%E3%80%8D%EC%97%90%EC%8A%A4%ED%8B%B0%ED%8C%9C_IR%282024.05%29.pdf?download=1"
    ],
    "verified_at": "2026-04-22",
    "zh": "圣诺医药"
  },
  "STP122G": {
    "confidence": "high",
    "en_full": "STP122G",
    "issue": "STP122G是圣诺医药(Sirnaomics)的在研药物代码，属于专有项目编号，无中文规范译名。建议保留英文原文。该药物为靶向十一因子(Factor XI)的GalNAc-siRNA抗凝血疗法。",
    "sources": [
      "https://sirnaomics.com/cn/news-room/press-release/20231205sirnaomics%E5%AE%A3%E5%B8%83%E5%9F%BA%E4%BA%8Egalnac-rnai%E7%96%97%E6%B3%95%E8%8D%AF%E7%89%A9stp122g%E7%94%A8%E4%BA%8E%E6%8A%97%E5%87%9D%E6%B2%BB%E7%96%97%E7%9A%84i%E6%9C%9F%E4%B8%B4%E5%BA%8A%E8%AF%95%E9%AA%8C%E7%AC%AC%E4%B8%80%E5%BA%8F%E5%88%97%E5%9C%86%E6%BB%A1%E5%AE%8C%E6%88%90/",
      "https://cnmobile.prnasia.com/story/453316-1.shtml",
      "https://www.jiemian.com/article/9225974.html"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "SUGAR-TARGET glycosyl-transferase cascade": {
    "confidence": "low",
    "en_full": "SUGAR-TARGET glycosyl-transferase cascade",
    "issue": "搜索结果未找到'SUGAR-TARGET'作为特定技术平台或专有名词的权威定义。current_zh中'级联反应'应改为'级联'更准确（cascade本身已含反应含义）。建议确认SUGAR-TARGET是否为特定公司/机构的专有技术平台名称，或为学术文献中的通用术语。",
    "sources": [
      "https://www.frontiersin.org/articles/10.3389/fphys.2021.629682/pdf",
      "https://link.springer.com/10.1038/s10038-026-01463-0?fromPaywallRec=true",
      "https://bydrug.pharmcube.com/news/detail/5858c7d65142b84cd3cdb5f50e302431"
    ],
    "verified_at": "2026-04-22",
    "zh": "SUGAR-TARGET糖基转移酶级联"
  },
  "Sangon Biotech": {
    "confidence": "medium",
    "en_full": "Sangon Biotech (Shanghai) Co., Ltd.",
    "issue": "current_zh '生工' 为不完整译名。根据搜索结果，Sangon Biotech 的中文规范译名应为'三工生物'（Sangon 音译为'三工'）。搜索结果[3]确认英文全称为 Sangon Biotech (Shanghai) Co., Ltd.，成立于2003年，总部在上海。",
    "sources": [
      "https://geneonline.news/%e7%be%85%e6%b0%8f%e8%88%87sangenebio%e5%90%88%e4%bd%9c%e5%8a%a0%e9%80%9frnai%e7%99%82%e6%b3%95%e9%96%8b%e7%99%bc/",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://synapse.patsnap.com/organization/62327745464f43d447fb488930d373b5"
    ],
    "verified_at": "2026-04-22",
    "zh": "三工生物"
  },
  "SiaT": {
    "confidence": "low",
    "en_full": "Sialic Acid Transporter",
    "issue": "搜索结果未直接涉及 SiaT 术语定义。SiaT 在双靶点 RNAi 药物领域的具体含义无法从提供的搜索片段中确认。建议补充搜索或人工核实该术语在相关文献中的准确定义和中文译法。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://www.drugtimes.cn/2026/02/02/shianshengwubaxiangalk7desirnajianfeixinyaoshixianquanqiuton/",
      "https://www.zhihuiya.com/news/info_11558.html"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Snake Venom Phosphodiesterase": {
    "confidence": "high",
    "en_full": "Snake Venom Phosphodiesterase",
    "issue": "",
    "sources": [
      "https://www.sciencedirect.com/science/article/pii/S004101012200232X",
      "https://pubmed.ncbi.nlm.nih.gov/37067034/",
      "https://www.ovid.com/journals/toxic/fulltext/10.1016/j.toxicon.2022.08.004~state-of-the-art-review-of-snake-venom-phosphodiesterases"
    ],
    "verified_at": "2026-04-22",
    "zh": "蛇毒磷酸二酯酶"
  },
  "Sollbruchstellen": {
    "confidence": "medium",
    "en_full": "Sollbruchstellen",
    "issue": "Sollbruchstellen 为德文术语，意为'断裂点'或'易断位点'，在寡核苷酸/siRNA 药物设计中指人为设计的易被核酸酶切割的位点，用于控制药物在体内的降解。current_zh '易断位点' 为合理的意译，但搜索结果未直接出现该德文术语的中文对照，建议补充验证是否有更规范的业内统一译法",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a",
      "https://bydrug.pharmcube.com/news/detail/701efaa54bcd58bf8ece7f222f8356c7"
    ],
    "verified_at": "2026-04-22",
    "zh": "易断位点"
  },
  "SpyCatcher/SpyTag": {
    "confidence": "high",
    "en_full": "SpyCatcher/SpyTag",
    "issue": "SpyCatcher/SpyTag是蛋白质工程领域的通用技术术语，无统一中文规范译名。中文文献中多保留英文原文或音译为'间谍捕手/间谍标签'，但业内通常直接使用英文。建议保留英文原文。",
    "sources": [
      "https://www.mabnus.cn/News-Trend/SpyTag-SpyCatcher-system-Protein-covalent-coupling-technology.html",
      "https://m.ebiotrade.com/Newsf/2026-1/20260113001824224.htm",
      "https://www.ovid.com/journals/molimmu/pdf/10.1016/j.molimm.2023.12.001~the-spycatcher-spytag-interaction-mediates-tunable"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Strain-Promoted Azide–Alkyne Cycloaddition": {
    "confidence": "high",
    "en_full": "Strain-Promoted Azide–Alkyne Cycloaddition",
    "issue": "",
    "sources": [
      "https://www.nature.com/articles/s42004-026-01927-6",
      "https://discovery.researcher.life/article/aggregation-induced-electrochemiluminescence-of-zirconium-metal-organic-framework-with-strain-promoted-azide-alkyne-cycloaddition-ligated-dna-tetrahedral-nanotags-for-microrna-detection/e60394c23bde3219b458b74d254a0df7",
      "https://manu56.magtech.com.cn/progchem/EN/10.7536/PC220103"
    ],
    "verified_at": "2026-04-22",
    "zh": "应变促进叠氮–炔烃环加成"
  },
  "Supply-Chain Opportunity Map": {
    "confidence": "medium",
    "en_full": "Supply-Chain Opportunity Map",
    "issue": "",
    "sources": [
      "https://www.hangyan.co/reports/3841585074373919805",
      "http://field.10jqka.com.cn/20260227/c674963072.shtml",
      "https://www.sohu.com/a/982375140_133140"
    ],
    "verified_at": "2026-04-22",
    "zh": "供应链机会地图"
  },
  "Suzhou Taike": {
    "confidence": "low",
    "en_full": "Suzhou Taike",
    "issue": "搜索结果未找到 'Suzhou Taike' 的相关信息。搜索返回的是苏州时安生物、Sirnaomics（圣诺生物）、瑞博生物等其他RNAi公司。建议确认术语拼写或公司全名，可能存在拼写错误或该公司名称不常见。",
    "sources": [
      "https://www.siranbio.com/news/html/?31.html=",
      "https://www.sirnaomics.com/en/news-room/press-release/20220621sirnaomics-to-present-the-latest-developments-of-dual-targeted-rnai-therapeutics-based-on-its-proprietary-galahead-program-at-the-4th-annual-rna-therapeutic-from-concept-to-clinic-symposium/",
      "https://www.mg21.com/ribobio.html"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Synthesis Modality": {
    "confidence": "low",
    "en_full": "Synthesis Modality",
    "issue": "搜索结果未能找到 'Synthesis Modality' 作为专业术语的权威定义。current_zh '合成模式' 为通用翻译，但在双靶点RNAi药物领域的具体含义不明确。建议确认该术语是否为特定技术平台名称、公司专有术语或学术概念，以获得更准确的中文规范译名。",
    "sources": [
      "https://news.yaozh.com/archive/46117.html",
      "https://www.163.com/dy/article/KPJP9NUA05349C3I.html?f=post2020_dy_recommends",
      "https://synapse.zhihuiya.com/report/c49ec658-dcee-4c82-984f-792a7b7650c1"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "T4 RNA Ligase 1": {
    "confidence": "high",
    "en_full": "T4 RNA Ligase 1",
    "issue": "",
    "sources": [
      "https://www.yeasen.com/h5/solutiondetail/3625",
      "https://www.yeasen.com/products/detail/5129",
      "https://www.yeasen.com/solutiondetail/3338"
    ],
    "verified_at": "2026-04-22",
    "zh": "T4 RNA连接酶1"
  },
  "T4 RNA Ligase 2": {
    "confidence": "high",
    "en_full": "T4 RNA Ligase 2",
    "issue": "",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/b46e648d440a805ce6cbf5da12b59514",
      "https://www.yeasenbio.com/it/blogs/news/synthesis-of-sirna-and-the-role-of-t4-rna-ligase-2",
      "https://www.geneseed.com.cn/m/productDesc/168.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "T4 RNA连接酶2"
  },
  "T7 RNA polymerase": {
    "confidence": "high",
    "en_full": "T7 RNA polymerase",
    "issue": "",
    "sources": [
      "https://pubmed.ncbi.nlm.nih.gov/39920702/",
      "https://www.sciencedirect.com/science/article/abs/pii/S0006291X07013423",
      "https://bydrug.pharmcube.com/news/detail/5e94553f5e9fa5ab7109092397468dd3"
    ],
    "verified_at": "2026-04-22",
    "zh": "T7 RNA聚合酶"
  },
  "TRL": {
    "confidence": "high",
    "en_full": "Technology Readiness Level",
    "issue": "current_zh '技术成熟度' 不够准确，业界标准译法为 '技术就绪度'，特别在研发管线评估中常用 TRL 1-9 分级体系",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://news.yaozh.com/archive/46117.html",
      "https://m.cphi.cn/news/show-361174.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "技术就绪度"
  },
  "TRiM™": {
    "confidence": "high",
    "en_full": "Trabecular Meshwork-targeted RNAi Molecule Platform",
    "issue": "",
    "sources": [
      "https://www.himd.com/health-discover/445703",
      "https://bydrug.pharmcube.com/news/detail/4f571bd0b6019f5b3fb3e3ce756f6eee",
      "https://ir.arrowheadpharma.com/static-files/8cfe7704-d80e-4fd6-9e03-4899251f8b7c"
    ],
    "verified_at": "2026-04-22",
    "zh": "TRiM™平台"
  },
  "Takara Bio": {
    "confidence": "high",
    "en_full": "Takara Bio Inc.",
    "issue": "current_zh 正确。Takara Bio 在中国的子公司为'宝生物工程（大连）有限公司'，母公司日本总部为 Takara Bio Inc.，中文通常统称为'宝生物工程'或'Takara Bio'",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/b46e648d440a805ce6cbf5da12b59514",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://synapse.zhihuiya.com/organization/458322cab0ced5818be2d13ae594cac5"
    ],
    "verified_at": "2026-04-22",
    "zh": "宝生物工程"
  },
  "Technical Guidelines for Pharmaceutical Research on Chemically Synthesized Oligonucleotide Drugs (Innovative Drugs)": {
    "confidence": "high",
    "en_full": "Technical Guidelines for Pharmaceutical Research on Chemically Synthesized Oligonucleotide Drugs (Innovative Drugs)",
    "issue": "",
    "sources": [
      "https://m.xfdyb.com/show-2471.html",
      "https://xfdyb.com/show-2471.html",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag"
    ],
    "verified_at": "2026-04-22",
    "zh": "化学合成寡核苷酸药物（创新药）药学研究技术指导原则（试行）"
  },
  "Terminal Deoxynucleotidyl Transferase": {
    "confidence": "high",
    "en_full": "Terminal Deoxynucleotidyl Transferase",
    "issue": "",
    "sources": [
      "https://www.sciencedirect.com/science/article/pii/S2667370324000419",
      "https://journal.hep.com.cn/engmic/EN/10.1016/j.engmic.2024.100179",
      "https://pubmed.ncbi.nlm.nih.gov/40538715/"
    ],
    "verified_at": "2026-04-22",
    "zh": "末端脱氧核苷酸转移酶"
  },
  "Tianjin Orilife": {
    "confidence": "high",
    "en_full": "Tianjin Orilife Biopharma Co., Ltd.",
    "issue": "current_zh '天津奥利法' 为错误译名，官网中文页面明确显示正式名称为 '天津奥瑞芙生物医药有限公司'，应更正",
    "sources": [
      "http://www.cnorilife.com/en/Product-center.html",
      "http://www.cnorilife.com/Contact.html",
      "http://www.cnorilife.com/en/Nucleoside-drug-intermediates-16.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "天津奥瑞芙生物医药有限公司"
  },
  "Tier 1": {
    "confidence": "medium",
    "en_full": "Tier 1",
    "issue": "Tier 1 在生物医药研发管线分类中通常指'第一阶段'或'第一梯队'，current_zh '第一层级' 可接受但'第一阶段'或'一线'可能更常见；搜索结果未直接涉及Tier 1定义，建议确认具体应用场景",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://news.yaozh.com/archive/46117.html",
      "https://www.zhihuiya.com/news/info_10813.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "第一层级"
  },
  "Tier 2": {
    "confidence": "low",
    "en_full": "Tier 2",
    "issue": "搜索结果未涉及 'Tier 2' 术语的定义或用法。在双靶点RNAi药物研发领域，'Tier 2' 可能指临床试验分级、公司规模分类或监管分类，但搜索片段无法确认其具体含义。建议补充搜索或提供更多上下文。current_zh '第二层级' 为推测性译法，缺乏权威依据。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag",
      "https://news.yaozh.com/archive/46117.html"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "Tier 3": {
    "confidence": "medium",
    "en_full": "Tier 3",
    "issue": "搜索结果未直接涉及'Tier 3'的定义或中文译法。'Tier 3'在RNAi药物研发语境中通常指临床试验分层或药物开发阶段分类，current_zh '第三层级'为合理推断译法，但缺乏权威来源直接确认。建议补充查证该术语在具体研发管线分类中的官方定义。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/d81cdcfde2947c1026889999ce66a7ae",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://mp.weixin.qq.com/s/jaHfnYV511qmM5y8N5VFtw"
    ],
    "verified_at": "2026-04-22",
    "zh": "第三层级"
  },
  "Triazole linker": {
    "confidence": "high",
    "en_full": "Triazole linker",
    "issue": "",
    "sources": [
      "https://www.eurekaselect.com/article/131388",
      "https://www.163.com/dy/article/K4BJM0VR0532CO9S.html",
      "https://pubs.rsc.org/en/content/articlepdf/2022/cb/d2cb00100d"
    ],
    "verified_at": "2026-04-22",
    "zh": "三唑接头"
  },
  "TrisGal-6 scaffold": {
    "confidence": "medium",
    "en_full": "TrisGal-6 scaffold",
    "issue": "",
    "sources": [
      "https://www.semanticscholar.org/paper/A-programmable-dual-targeting-siRNA-scaffold-potent-Belgrad-Tang/8d9b46f15845339abdea08e35f5910c265e574d7",
      "https://pmc.ncbi.nlm.nih.gov/articles/PMC10928129/",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag"
    ],
    "verified_at": "2026-04-22",
    "zh": "TrisGal-6骨架"
  },
  "UDP-Gal": {
    "confidence": "high",
    "en_full": "Uridine Diphosphate Galactose",
    "issue": "",
    "sources": [
      "https://m.gelonghui.com/p/1230779",
      "https://tides.wuxiapptec.com/cn/resources/sirna-galnac-%E6%A1%88%E4%BE%8B%E5%88%86%E4%BA%AB%EF%BC%9A10%E4%B8%AA%E6%9C%88%E5%86%85%E5%B0%86%E4%B8%80%E4%B8%AA-sirna-galnac-%E5%80%99%E9%80%89%E5%8C%96%E5%90%88%E7%89%A9%E6%8E%A8%E8%BF%9B%E8%87%B3/",
      "https://www.ebiotrade.com/newsf/2025-6/20250616183504731.htm"
    ],
    "verified_at": "2026-04-22",
    "zh": "尿苷二磷酸半乳糖"
  },
  "UDP-GalNAc": {
    "confidence": "high",
    "en_full": "Uridine Diphosphate N-Acetylgalactosamine",
    "issue": "current_zh 为英文缩写形式，应规范为中文全称或保留英文缩写；根据生物医药领域通行译法，UDP-GalNAc 的中文规范译名为'尿苷二磷酸-N-乙酰半乳糖胺'，在 RNAi 药物递送领域广泛应用",
    "sources": [
      "https://blog.csdn.net/xbakbio/article/details/141399270",
      "https://tides.wuxiapptec.com/cn/resources/sirna-galnac-%E6%A1%88%E4%BE%8B%E5%88%86%E4%BA%AB%EF%BC%9A10%E4%B8%AA%E6%9C%88%E5%86%85%E5%B0%86%E4%B8%80%E4%B8%AA-sirna-galnac-%E5%80%99%E9%80%89%E5%8C%96%E5%90%88%E7%89%A9%E6%8E%A8%E8%BF%9B%E8%87%B3/",
      "https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/fc1d64676d2f6345dfeffa0b30afa358"
    ],
    "verified_at": "2026-04-22",
    "zh": "尿苷二磷酸-N-乙酰半乳糖胺"
  },
  "Unylinker-functionalized polystyrene support": {
    "confidence": "high",
    "en_full": "Unylinker-functionalized polystyrene support",
    "issue": "",
    "sources": [
      "https://www.biosearchtech.com/nucleic-acid-chemistry-reagents-and-instruments/unmodified-oligo-synthesis-reagents/universal-synthesis/polystyrene/unylinker%E2%84%A2-polystyrene/p/PS1-1001-B",
      "https://www.csccyy.cn/sycxq/1134047115464769536.html",
      "https://www2.lgcgroup.com/l/31922/2024-04-16/wjjkq9"
    ],
    "verified_at": "2026-04-22",
    "zh": "Unylinker功能化聚苯乙烯载体"
  },
  "Vazyme": {
    "confidence": "high",
    "en_full": "Nanjing Vazyme Biotech Co., Ltd.",
    "issue": "",
    "sources": [
      "https://rnaibased-therapeutics.com/sponsor/vazyme/",
      "https://synapse.patsnap.com/organization/e0137e3deac890694c1890b01a73b344",
      "http://www.vazyme.com/"
    ],
    "verified_at": "2026-04-22",
    "zh": "诺唯赞"
  },
  "Worthington Biochemical": {
    "confidence": "medium",
    "en_full": "Worthington Biochemical Corporation",
    "issue": "Worthington Biochemical 是生化试剂供应商，与双靶点RNAi药物研发领域关联度低。搜索结果主要显示其中国代理商（上海优宁维生物）的产品信息，未找到该公司在RNAi药物研发中的直接角色。建议确认术语出现的具体上下文。",
    "sources": [
      "http://worthington-biochem.com.cn/?list_21%2F59.html=",
      "https://news.yaozh.com/archive/46117.html",
      "https://univ.biomart.cn/supply/c_agency-4028487718bc5d980118bd277fc40069_trademark-Worthington.htm"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "WuXi AppTec": {
    "confidence": "high",
    "en_full": "WuXi AppTec Co., Ltd.",
    "issue": "",
    "sources": [
      "https://labtesting.wuxiapptec.com/2025/07/10/3-therapeutic-considerations-for-the-future-of-oligonucleotide-development/",
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://officialsite-static.wuxiapptec.com/upload/12/20240904/Interim%20Report%202024.pdf"
    ],
    "verified_at": "2026-04-22",
    "zh": "药明康德"
  },
  "Wuhu Huaren": {
    "confidence": "high",
    "en_full": "Wuhu Huaren Science & Technology Co., Ltd.",
    "issue": "",
    "sources": [
      "https://synapse.patsnap.com/organization/07c68b8d2f13cc93eea6175f2bb42756",
      "https://www.163.com/dy/article/KQV0MKQK0552IJOG.html?f=post2020_dy_recommends",
      "https://www.huarenscience.com/company-profile/"
    ],
    "verified_at": "2026-04-22",
    "zh": "芜湖华仁"
  },
  "XBP-1": {
    "confidence": "high",
    "en_full": "X-box Binding Protein 1",
    "issue": "",
    "sources": [
      "https://www.medsci.cn/search?module=&page=2&q=XBP1%E4%BB%8B%E5%AF%BC&search_type=1&sort_type=2&time_type=0",
      "https://www.medsci.cn/search?module=&page=3&q=X-box%E7%BB%93%E5%90%88%E8%9B%8B%E7%99%BD1%EF%BC%88XBP1s%EF%BC%89&search_type=1&sort_type=1&time_type=0",
      "https://www.scbt.com/de/p/xbp-1-sirna-h-shrna-and-lentiviral-particle-gene-silencers"
    ],
    "verified_at": "2026-04-22",
    "zh": "X-box结合蛋白1"
  },
  "Yeasen Biotech": {
    "confidence": "high",
    "en_full": "Yeasen Biotechnology (Shanghai) Co., Ltd.",
    "issue": "",
    "sources": [
      "https://synapse.zhihuiya.com/organization/30f34c9cd3414ace471fad8d2e03fecc",
      "https://www.yeasen.com/h5/solutiondetail/1945743326406934528",
      "https://www.yeasenbio.com/blogs/news"
    ],
    "verified_at": "2026-04-22",
    "zh": "翌圣生物科技"
  },
  "acceptable daily intake": {
    "confidence": "high",
    "en_full": "Acceptable Daily Intake",
    "issue": "",
    "sources": [
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://bydrug.pharmcube.com/report/detail/c38fc881773444bebb80f59a21c45818"
    ],
    "verified_at": "2026-04-22",
    "zh": "每日可接受摄入量"
  },
  "activated-intermediate shelf life": {
    "confidence": "low",
    "en_full": "activated-intermediate shelf life",
    "issue": "搜索结果未包含该术语的定义或使用案例。'activated-intermediate shelf life' 可能是RNAi药物合成中的专业术语，指活化中间体的稳定性/保存期限，但无权威文献支持其中文译名。建议保留英文原文或查阅相关合成化学文献确认。current_zh '活化中间体货架期' 的逻辑合理但缺乏来源验证。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "anion-exchange polishing": {
    "confidence": "medium",
    "en_full": "anion-exchange polishing",
    "issue": "搜索结果主要涉及双靶点寡核苷酸药物研发综述和anion exchanger蛋白靶点研究，未直接验证'anion-exchange polishing'的中文译名。但'阴离子交换精制'是该技术在生物制药纯化领域的业内通行译法，符合层析纯化术语规范。建议保留current_zh。",
    "sources": [
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2011.01521.x"
    ],
    "verified_at": "2026-04-22",
    "zh": "阴离子交换精制"
  },
  "antisolvent": {
    "confidence": "medium",
    "en_full": "antisolvent",
    "issue": "搜索结果主要涉及抗体-siRNA偶联药物、双特异性抗体、双靶点寡核苷酸药物等领域内容，未直接出现'antisolvent'术语的定义或中文译法。'反溶剂'是化学/制药工艺中的常用术语，指用于沉淀或析出目标物质的溶剂，current_zh译名符合业内通行用法，但本次搜索未能从权威源获得直接验证。",
    "sources": [
      "https://pdfs.cir.cn/ITTongXun/97/%E6%8A%97%E4%BD%93-siRNA%E5%81%B6%E8%81%94%E8%8D%AF%E7%89%A9%E7%9A%84%E7%8E%B0%E7%8A%B6%E4%B8%8E%E5%89%8D%E6%99%AF_5022697.pdf",
      "https://news.qq.com/rain/a/20260124A06K3C00",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": "反溶剂"
  },
  "arm-coupling reaction": {
    "confidence": "medium",
    "en_full": "arm-coupling reaction",
    "issue": "搜索结果主要涉及双靶点寡核苷酸药物的偶联策略概念，但未直接出现 'arm-coupling reaction' 的英文术语定义或中文对应表述。'臂偶联反应' 作为 current_zh 在寡核苷酸药物领域具有合理性（arm 指寡核苷酸的臂结构，coupling 指偶联），但缺乏权威文献直接确认。建议补充查证专业文献或Alnylam等企业的技术文档以提高可信度。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag",
      "https://news.yaozh.com/archive/46117.html"
    ],
    "verified_at": "2026-04-22",
    "zh": "臂偶联反应"
  },
  "atom-economy penalty": {
    "confidence": "medium",
    "en_full": "atom-economy penalty",
    "issue": "搜索结果未直接出现'atom-economy penalty'术语的定义或中文对应表述。'原子经济性损失'为化学合成领域的学术用语，在双靶点RNAi药物偶联策略背景下可能指合成过程中的原子利用效率损失。建议确认该术语是否为原文中的准确表述，或查阅相关合成化学文献以验证。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://mp.weixin.qq.com/s/5L1N4w-0e7CV2SdyUZ5AAg",
      "https://mp.weixin.qq.com/s/jaHfnYV511qmM5y8N5VFtw"
    ],
    "verified_at": "2026-04-22",
    "zh": "原子经济性损失"
  },
  "avidity plateau": {
    "zh": "亲合力平台"
  },
  "bead attrition": {
    "confidence": "medium",
    "en_full": "bead attrition",
    "issue": "搜索结果主要涉及siRNA药物研发和氧化锆微珠材料学，未直接验证'bead attrition'在双靶点RNAi药物研发中的具体应用背景。current_zh'微珠磨损'为合理的字面翻译，但建议确认是否为该领域的规范术语。",
    "sources": [
      "https://journal.mrs-k.or.kr/articles/xml/bPkZ/",
      "https://bydrug.pharmcube.com/news/detail/be97e6c870c76f26dfe3394a98047c9b",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": "微珠磨损"
  },
  "bottom-up mapping": {
    "confidence": "medium",
    "en_full": "bottom-up mapping",
    "issue": "搜索结果未直接出现'bottom-up mapping'的定义或中文对应表述。'自下而上图谱分析'为合理的字面翻译，但在双靶点RNAi药物研发领域的具体含义需人工确认。建议补充查证该术语在药物靶点发现或信号通路分析中的确切应用场景。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://www.phirda.com/artilce_26418.html",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": "自下而上图谱分析"
  },
  "branching-point coupling": {
    "confidence": "medium",
    "en_full": "branching-point coupling",
    "issue": "搜索结果主要涉及'双靶点寡核苷酸药物偶联策略'的概念讨论，但未直接出现'branching-point coupling'的英文术语或其中文对应表述。current_zh '分支点偶联'为合理的字面翻译，符合RNAi双靶点药物领域的技术语境（指多个siRNA通过分支结构进行偶联），但缺乏权威文献直接确认。建议后续查证学术文献或专利文献以提高可信度。",
    "sources": [
      "https://www.mdpi.com/1424-8247/18/12/1844",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://mp.weixin.qq.com/s/ZRjEgqgPFikXSEOMGtaLag"
    ],
    "verified_at": "2026-04-22",
    "zh": "分支点偶联"
  },
  "bundled enzyme-carrier product": {
    "confidence": "low",
    "en_full": "bundled enzyme-carrier product",
    "issue": "搜索结果未直接涉及 'bundled enzyme-carrier product' 术语的定义或中文译法。current_zh 为逐字直译，但无权威来源验证。建议补充搜索该术语在RNAi递送技术中的具体应用背景以确认准确性。",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "https://bydrug.pharmcube.com/report/detail/dc4d25c8d5264e13a42b58955097be1a"
    ],
    "verified_at": "2026-04-22",
    "zh": "酶-载体捆绑产品"
  },
  "cardiometabolic disease": {
    "confidence": "high",
    "en_full": "cardiometabolic disease",
    "issue": "",
    "sources": [
      "https://view.inews.qq.com/a/20260118A069KA00",
      "https://www.163.com/dy/article/KPJP9NUA05349C3I.html?f=post2020_dy_recommends",
      "https://www.sanegenebio.com/cn_Science_Pipeline/"
    ],
    "verified_at": "2026-04-22",
    "zh": "心脏代谢疾病"
  },
  "cell-free synthesis": {
    "confidence": "high",
    "en_full": "cell-free synthesis",
    "issue": "",
    "sources": [
      "https://www.nature.com/articles/s41392-024-02112-8",
      "https://en.dascapital.cn/%E8%A1%8C%E7%A0%94-rna%E6%97%B6%E4%BB%A3%E5%8A%A0%E9%80%9F%EF%BC%9Frna%E8%B5%9B%E9%81%93%E6%A2%B3%E7%90%86/",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": "无细胞合成"
  },
  "channeling": {
    "confidence": "low",
    "en_full": "channeling",
    "issue": "搜索结果未包含 'channeling' 术语的定义或应用说明。在 RNAi 药物研发背景下，'channeling' 可能指分子通道、信号转导通道或药物递送通道等，但无法从提供的搜索片段确认其具体含义和规范中文译法。current_zh '沟流' 缺乏权威支持。建议补充搜索或人工确认该术语在双靶点 RNAi 药物研发中的具体应用场景。",
    "sources": [
      "http://stock.10jqka.com.cn/20260407/c675785918.shtml",
      "http://field.10jqka.com.cn/20260227/c674963072.shtml",
      "https://mp.weixin.qq.com/s/jaHfnYV511qmM5y8N5VFtw"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "charge-state deconvolution": {
    "zh": "电荷态反卷积"
  },
  "chemoenzymatic": {
    "zh": "化学酶法"
  },
  "choline chloride/glycerol": {
    "zh": "氯化胆碱/甘油"
  },
  "choline chloride/urea (reline)": {
    "zh": "氯化胆碱/尿素（reline）"
  },
  "class extension": {
    "zh": "品类延伸"
  },
  "clinical translation": {
    "zh": "临床转化"
  },
  "cluster-arm variants": {
    "zh": "簇臂变体"
  },
  "co-dosing program": {
    "zh": "联合给药项目"
  },
  "cocktail formulation": {
    "zh": "鸡尾酒制剂"
  },
  "complement dysregulation": {
    "zh": "补体失调"
  },
  "continuous process verification": {
    "zh": "连续工艺验证"
  },
  "continuous-flow microgel reactor": {
    "zh": "连续流微凝胶反应器"
  },
  "control threshold": {
    "zh": "控制阈值"
  },
  "convergent assembly": {
    "zh": "汇聚式组装"
  },
  "copper scavenging": {
    "zh": "铜清除"
  },
  "copper-residue burden": {
    "zh": "铜残留合规负担"
  },
  "coronary heart disease": {
    "zh": "冠心病"
  },
  "covalently-linked tandem siRNA": {
    "zh": "共价连接串联siRNA"
  },
  "cross-activity": {
    "zh": "交叉活性"
  },
  "denaturing IP-RP-LC-MS": {
    "zh": "变性离子对反相液相色谱-质谱"
  },
  "dendritic scaffold": {
    "zh": "树枝状骨架"
  },
  "design paradigm": {
    "zh": "设计范式"
  },
  "di-valent branched construct": {
    "zh": "二价分支构建体"
  },
  "diamine scaffold": {
    "zh": "二胺骨架"
  },
  "disulfide bond": {
    "zh": "二硫键"
  },
  "domestic-substitution feasibility": {
    "zh": "国产替代可行性"
  },
  "droplet microfluidics": {
    "zh": "液滴微流控技术"
  },
  "dsRNA": {
    "zh": "dsRNA"
  },
  "dual-functional RNAi therapeutic": {
    "confidence": "high",
    "en_full": "dual-functional RNAi therapeutic",
    "issue": "current_zh '双功能RNAi治疗药物' 应改为 '双靶点RNAi治疗药物'。搜索结果中权威医药媒体（智慧芽、医药魔方、医麦客）均使用 '双靶点siRNA' 或 '双靶点RNAi' 的表述，'双靶点' 是业内标准术语，而非 '双功能'",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://bydrug.pharmcube.com/news/detail/5c2d51491c51f91c928223b445db5db3",
      "https://www.creative-biogene.com/blog/scientists-develop-dual-targeting-rnai-molecule"
    ],
    "verified_at": "2026-04-22",
    "zh": "双靶点RNAi治疗药物"
  },
  "enantiomeric excess": {
    "confidence": "high",
    "en_full": "enantiomeric excess",
    "issue": "",
    "sources": [
      "https://www.zhihuiya.com/news/info_12579.html",
      "https://www.multitran.com/zh/dictionary/english-chinese/enantiomeric%20excess",
      "http://dict.youdao.com/w/%E5%AF%B9%E6%98%A0%E4%BD%93%E8%BF%87%E9%87%8F/"
    ],
    "verified_at": "2026-04-22",
    "zh": "对映体过量"
  },
  "enzymatic-ligation": {
    "confidence": "high",
    "en_full": "enzymatic ligation",
    "issue": "",
    "sources": [
      "https://www.insights.bio/nucleic-acid-insights/journal/article/3716/industry-insights-advances-in-enzymatic-manufacturing-therapeutic-pipelines-and-regulatory-pathways-for-nucleic-acid-therapeutics",
      "https://lifesciencesglobalnews.com/alnylam-enzymatic-ligation-platform-rnai-manufacturing/",
      "https://www.insights.bio/api/article/3716/download"
    ],
    "verified_at": "2026-04-22",
    "zh": "酶连接"
  },
  "enzyme loading per gram": {
    "confidence": "medium",
    "en_full": "enzyme loading per gram",
    "issue": "current_zh '每克载体酶载量' 表述冗余，'载体'为修饰词不必要；规范表述应为'每克酶载量'或'单位质量酶载量'。搜索结果未直接出现该术语的标准中文表述，但根据生物制药领域常用术语规范，'enzyme loading per gram' 对应'每克酶载量'为业内通行译法。",
    "sources": [
      "https://bydrug.pharmcube.com/news/detail/f22a4b575c0ca43161b5ae2e98f0af0b",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3",
      "https://bydrug.pharmcube.com/report/detail/c38fc881773444bebb80f59a21c45818"
    ],
    "verified_at": "2026-04-22",
    "zh": "每克酶载量"
  },
  "fixed-bed copper-scavenging resin": {
    "confidence": "low",
    "en_full": "fixed-bed copper-scavenging resin",
    "issue": "搜索结果无有效信息支持该术语的中文译名。搜索结果涉及铜吸附材料、铜基纳米催化剂等相关研究，但未找到'fixed-bed copper-scavenging resin'的权威中文表达或英文全称定义。该术语可能是特定工艺/技术术语，建议保留英文原文，待获得更多权威文献支持后再确定中文译名。",
    "sources": [
      "https://www.ebiotrade.com/newsf/2025-5/20250526111657553.htm",
      "http://blog.sciencenet.cn/blog-3411509-1523903.html",
      "https://bydrug.pharmcube.com/news/detail/ab51a539cf4cf8a79ec1c02ef45552a3"
    ],
    "verified_at": "2026-04-22",
    "zh": ""
  },
  "glutaraldehyde": {
    "confidence": "high",
    "en_full": "glutaraldehyde",
    "issue": "",
    "sources": [
      "https://www.targetmol.cn/news/Molecular_Glue_introduction",
      "https://bydrug.pharmcube.com/news/detail/be766b5b289bb633a5a33b0bcd32159d",
      "https://www.gluetacs.com/20240531/"
    ],
    "verified_at": "2026-04-22",
    "zh": "戊二醛"
  },
  "glycosyl-transferase": {
    "confidence": "high",
    "en_full": "glycosyl-transferase",
    "issue": "",
    "sources": [
      "https://news.bioon.com/article/1c828e529184.html",
      "https://pubmed.ncbi.nlm.nih.gov/33841170/",
      "https://bydrug.pharmcube.com/news/detail/5858c7d65142b84cd3cdb5f50e302431"
    ],
    "verified_at": "2026-04-22",
    "zh": "糖基转移酶"
  },
  "hepatic parenchymal clearance": {
    "zh": "肝实质清除率"
  },
  "hetero-duplex": {
    "zh": "异源双链体"
  },
  "hexaethyleneglycol": {
    "zh": "六乙二醇"
  },
  "hexavalent GalNAc cluster": {
    "zh": "六价GalNAc簇"
  },
  "high-load polymeric support": {
    "zh": "高载量聚合物载体"
  },
  "homo-duplex": {
    "zh": "同源双链体"
  },
  "hypertriglyceridemia": {
    "zh": "高甘油三酯血症"
  },
  "immobilized enzyme": {
    "zh": "固定化酶"
  },
  "immobilized polymerase/phosphatase reactor": {
    "zh": "固定化聚合酶/磷酸酶反应器"
  },
  "inline conversion monitoring": {
    "zh": "在线转化率监测"
  },
  "inter-lot specific activity variation": {
    "zh": "批间比活力变异"
  },
  "junction-verification assay": {
    "zh": "连接位点验证检测"
  },
  "lenticular beads": {
    "zh": "扁豆形微珠"
  },
  "lipid nanoparticle": {
    "zh": "脂质纳米颗粒"
  },
  "liquid-phase oligonucleotide synthesis": {
    "zh": "液相寡核苷酸合成"
  },
  "liquid-phase synthesis": {
    "zh": "液相合成"
  },
  "mRNAi GOLD™": {
    "zh": "mRNAi GOLD™"
  },
  "maleimide-activated agarose": {
    "zh": "马来酰亚胺活化琼脂糖"
  },
  "manufacturing stack": {
    "zh": "制造体系"
  },
  "material diversion strategy": {
    "zh": "物料转移策略"
  },
  "membrane bioreactor": {
    "zh": "膜生物反应器"
  },
  "methacrylate copolymer beads": {
    "zh": "甲基丙烯酸酯共聚物微珠"
  },
  "mixed hyperlipidemia": {
    "zh": "混合型高脂血症"
  },
  "monoantennary GalNAc": {
    "zh": "单天线GalNAc"
  },
  "monomer diversity index": {
    "zh": "单体多样性指标"
  },
  "muRNA": {
    "zh": "muRNA"
  },
  "multivalent GalNAc cluster": {
    "zh": "多价GalNAc簇"
  },
  "multivalent GalNAc scaffold": {
    "zh": "多价GalNAc骨架"
  },
  "murine TdT": {
    "zh": "鼠源TdT"
  },
  "mxRNA": {
    "zh": "mxRNA"
  },
  "neurodegeneration": {
    "zh": "神经退行性疾病"
  },
  "nonclinical guidance": {
    "zh": "非临床指南"
  },
  "nuclease mapping": {
    "zh": "核酸酶图谱分析"
  },
  "packed-bed reactor": {
    "zh": "填充床反应器"
  },
  "partially conjugated strand": {
    "zh": "部分偶联链"
  },
  "particle-integrity monitoring": {
    "zh": "颗粒完整性监测"
  },
  "pentavalent GalNAc": {
    "zh": "五价GalNAc"
  },
  "phosphoramidite monomer": {
    "confidence": "high",
    "en_full": "phosphoramidite monomer",
    "issue": "",
    "sources": [
      "https://broadpharm.com/blog/Modified-Phosphoramidites-in-RNAi-Research",
      "https://www.ractigen.com/sirna-aco-is-a-convenient-phosphoramidite-based-conjugate-that-enables-rnai-in-the-cns-via-local-administration-with-superior-efficacy-in-the-treatment-of-als-rodent-models-poster/",
      "https://pmc.ncbi.nlm.nih.gov/articles/PMC11472056/"
    ],
    "verified_at": "2026-04-22",
    "zh": "亚磷酰胺单体"
  },
  "pipeline inflation": {
    "zh": "管线虚胖"
  },
  "platform-multiplication event": {
    "zh": "平台倍增事件"
  },
  "polymer microgels": {
    "zh": "聚合物微凝胶"
  },
  "pre-validated package": {
    "zh": "预验证文件包"
  },
  "pressure-drop effects": {
    "zh": "压降效应"
  },
  "process debt": {
    "zh": "工艺债务"
  },
  "process node": {
    "zh": "工艺节点"
  },
  "process signature": {
    "zh": "工艺特征"
  },
  "product-specific guidance": {
    "zh": "产品专项指南"
  },
  "protecting-group strategy": {
    "zh": "保护基策略"
  },
  "protective allele": {
    "zh": "保护性等位基因"
  },
  "pyranose": {
    "zh": "吡喃糖"
  },
  "qualification barrier": {
    "zh": "资质壁垒"
  },
  "rSAP": {
    "zh": "rSAP"
  },
  "ratio QC": {
    "zh": "比例质控"
  },
  "receptor-mediated uptake": {
    "zh": "受体内吞"
  },
  "regulatory vector": {
    "zh": "监管向量"
  },
  "release-profile QC": {
    "zh": "释放谱质控"
  },
  "residual enzyme surveillance": {
    "zh": "残留酶监控"
  },
  "ribofuranose scaffold": {
    "zh": "核糖呋喃糖骨架"
  },
  "serially assembled trivalent construct": {
    "zh": "序贯组装三价构建体"
  },
  "siRELIS facility": {
    "zh": "siRELIS工厂"
  },
  "silica bead fines": {
    "zh": "硅胶微珠细粉"
  },
  "solid-phase phosphoramidite synthesis": {
    "zh": "固相亚磷酰胺合成"
  },
  "solid-phase synthesis": {
    "zh": "固相合成"
  },
  "soluble anchor": {
    "zh": "可溶性锚定基团"
  },
  "spacer accessibility": {
    "zh": "间隔臂可及性"
  },
  "splint removal": {
    "zh": "DNA夹板去除"
  },
  "streptavidin-coated silica beads": {
    "zh": "链霉亲和素包被硅胶微珠"
  },
  "structure-activity study": {
    "zh": "构效关系研究"
  },
  "sub-saturation binding regime": {
    "zh": "未饱和结合区间"
  },
  "supplier concentration": {
    "zh": "供应商集中度"
  },
  "swelling index": {
    "zh": "溶胀指数"
  },
  "tetraantennary": {
    "zh": "四天线"
  },
  "tetraloop": {
    "zh": "四环体"
  },
  "top-down intact-mass sequencing": {
    "zh": "自上而下完整质量测序"
  },
  "toxicokinetic subfactor justification": {
    "zh": "毒代动力学亚因子论证"
  },
  "triantennary GalNAc": {
    "zh": "三天线GalNAc"
  },
  "truncated cluster impurity": {
    "zh": "截短型簇杂质"
  }
}
